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 Atrial fibrillation (AF) is the most common sustained arrhythmia in human patients, and 
is associated with an increased risk of stroke and other morbidity.  Acute-onset AF is frequently 
associated with cardiothoracic surgery, and its initiation is thought to involve proinflammatory 
signaling.  Activated neutrophils are known to be arrhythmogenic, and one of the inflammatory 
mediators released from neutrophils that contributes to arrhythmogenicity is the phospholipid 
platelet-activating factor (PAF).  PAF acts via a G-protein coupled receptor, present in myocytes, 
to activate downstream signaling cascades.  Data from our lab indicates that inhibition of the 
two-pore domain potassium channel TASK-1 may contribute to the arrhythmogenic effect of 
PAF.  This study describes the identification of a novel phosphorylation site in the human 
TASK-1 carboxyl terminus, T383, and has explored the association between phosphorylation at 
this site and the development or maintenance of various models of atrial fibrillation. 
 Signaling downstream of PAF was previously shown to inhibit the two pore-domain 
potassium channel TASK-1.  This inhibition required the activity of the epsilon isoform of 
protein kinase C (PKCε), and a putative phosphorylation site was identified in the murine 
TASK-1 channel.  In this thesis, I have identified a homologous phosphorylation site in the 
  
human TASK-1 channel, T383, and have demonstrated that this site is targeted in native atrial 
myocardium. 
 The known pro-inflammatory effects of PAF, as well as the action potential abnormalities 
observed in previous studies after direct TASK-1 antagonism in isolated mouse ventricular 
myocytes, suggested that inhibitory phosphorylation at T383 could play a role in arrhythmias, 
particularly those with an inflammatory component to their etiology.  Therefore, an aim of this 
thesis was to investigate the relationship between inhibitory TASK-1 phosphorylation and peri-
operative atrial fibrillation (POAF) in a canine model.  POAF is an acute onset of atrial 
fibrillation, with a known inflammatory component.  This thesis describes the association of 
POAF with increased infiltration of neutrophils into atrial myocardium and the phosphorylation-
dependent inhibition of TASK-1.  Furthermore, this thesis has demonstrated that 
phosphorylation-dependent inhibition of TASK-1 is also associated with sustained atrial 
fibrillation (AF), in a canine model of chronic AF and in human patients.  However, in chronic 
AF models, phosphorylation at T383 is not responsible for inhibition of the channel, and TASK-
1 inhibition is caused by phosphorylation of another as yet unidentified site.  Since TASK-1 
inhibition is associated with AF in both animal models and in human patients, and in both the 
acute and chronic disease, TASK-1 could be a new drug target for improved pharmacotherapy in 
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CHAPTER 1: INTRODUCTION 
 
Atrial fibrillation 
 Atrial Fibrillation (AF) is the most common sustained arrhythmia in humans, and can 
lead to an increased risk of stroke or other morbidity.  The tachycardic and irregular beating of 
the atria results in inefficient contraction and pooling of blood, promoting thrombosis.  Due to 
the loss of the atrial contribution to cardiac output and the possible conduction of irregular atrial 
electrical signaling to the ventricles (resulting in rapid and irregular ventricular beats and a 
further loss of cardiac output), AF is associated with an increased risk of heart failure (reviewed 
by Shah et al, 2010).  When compared to heart patients in normal sinus rhythm, patients with AF 
had a 50-150% increased mortality, across various studies when corrected for age, sex, and other 
cardiovascular risk factors (Greenlee and Vidaillet, 2005). 
 It has been proposed that the initiation and maintenance of clinical AF requires 1) a 
trigger; 2) a vulnerable substrate; and 3) modulatory factors such as the autonomic nervous 
system and inflammation, known as Coumel's triangle of arrhythmogenesis (Farré and Wellens, 
2004).  When a cardiomyocyte "fires" outside of the signal propagation initiated by the sinoatrial 
node due, for example, to altered calcium handling in the sarcoplasmic reticulum or automaticity 
in the pulmonary veins, an ectopic beat may result.  If the atrial substrate has been made 
vulnerable through structural or electrical changes, ectopic activity may trigger the initiation of a 





in the refractive period, and atrial dilation and fibrosis which may decrease conduction velocity, 
are often associated with disease and aging (reviewed by Wakili et al 2011; Allessie et al, 2001). 
 
Ectopic and triggered activity 
 Ectopic activity contributing to AF may initiate due to triggered activity or to abnormal 
automaticity.  Triggered activity can occur when voltage oscillations reach the threshold for 
activation of depolarizing currents, at an irregular place in the action potential cycle, triggering a 
second spike of inward current termed an afterdepolarization.  This can occur when the cycle 
length and action potential duration decrease, and a delayed afterdepolarization (DAD) occurs 
late in the repolarization cycle, likely due to dysfunction of the sarcoplasmic reticulum causing 
increased cytosolic calcium.  DADs are favored by conditions causing calcium overload, like 
tachycardia and β-adrenergic stimulation.  Triggered activity may also manifest as early 
afterdepolarizations (EADs), which occur during the plateau phase of prolonged action 
potentials.  At voltages near the threshold for calcium channel inactivation, calcium currents may 
become reactivated, triggering depolarization.  Spontaneous Ca2+ release from the sarcoplasmic 
reticulum, due to elevated cytosolic calcium, may also contribute to the occurrence of EADs, 
especially under conditions of β-adrenergic stimulation (reviewed by Schotten et al, 2011). 
 It has been proposed that an important site of ectopic activity in the heart is in the atrial 
musculature extending into the pulmonary veins, and to a lesser extent the coronary sinus, vena 
cavae, ligament of Marshall, mitral valves, and working atrial muscle itself.  While direct in vivo 
demonstrations of triggered activity in these regions initiating atrial arrhythmias are lacking 





regions as ectopic foci in human patients with AF (Haissaguerre et al, 1998; Volkmer et al, 2002; 
Tsai et al, 2000) and in animal models of atrial stretch-related AF (Kalifa et al, 2003), and AF 
related to pacing-induced heart failure (Okuyama et al, 2003).  The electrophysiological 
properties of pulmonary vein myocytes make them reasonable candidates for ectopic activity, 
due to their more depolarized resting membrane potential, slower upstroke velocity, and shorter 
action potential duration relative to atrial myocytes (Erlich et al, 2003).  The pulmonary vein 
musculature also contains a dense distribution of sympathetic and parasympathetic nerve endings 
to modulate refractoriness and calcium loading, as discussed in below.  Automaticity and a 
propensity for DADs and EADs have been demonstrated in isolated cells from the pulmonary 
vein (Perez-Lugones et al, 2003; Nattel 2003), although it is unclear to what extent the observed 
activity of isolated cells in a relatively artificial environment translates to the whole animal.  
 
Reentry 
 A reentrant wave may form when an activating impulse collides with structurally or 
electrically heterogeneous tissue in its path, forcing the wave to break around it, and initiating 
aberrant circuits.  As activating current moves along atrial tissue, the refractory period of the 
cells (that is, the delay of recovery of excitability after the last action potential) is determined by 
the voltage-dependent inactivation of inward currents, which is in turn determined by the action 
potential duration.  An aberrant activating circuit can only re-activate previously excited cells 
after this refractory period has passed.  Therefore, a shorter refractory period, slower conduction 
velocity, and larger atrial surface area favor reentry (reviewed by Schotten et al, 2011).  In 





around, or simply by introducing premature beats.  If refractoriness is variable, as is commonly 
seen in human patients with substantial fibrosis and atrial dilation, current may travel in multiple 
wavelets down a path of least refractory resistance, and possibly form sustained rotors (Vaquero 
et al, 2008). 
 
Remodeling 
 The changes to the atrium resulting in a substrate that promotes AF are termed 
remodeling, and are generally characterized as structural or electrical. 
 Electrical remodeling describes the series of changes in ion channel function and 
expression, and cell-to-cell conductivity that sustain the arrhythmia. AF remodeling is 
characterized by a decrease in the action potential duration (APD), as cells adapt to an increased 
atrial rate, and a resulting decrease in refractoriness.  The shortening of the refractory period, the 
period in which sodium channels are inactivated, means that the cell is more vulnerable to 
reentry.  The action potential duration is largely determined by the balance of inward calcium 
currents and outward potassium currents during the plateau phase.  In cells from a canine rapid-
pacing model of AF, Yue et al (1997) found that the density of L-type calcium current (ICaL) and 
transient outward potassium current (Ito; active in early repolarization) decreased progressively 
as the duration of tachycardic pacing increased.  Yagi et al (2002) observed a decrease in ICaL in 
cells from dogs with sustained and nonsustained AF after tachycardic pacing, but determined that 
the decreases observed in nonsustained AF were due to calcium-dependent inactivation 
processes, whereas in sustained AF current density was decreased by some other mechanism.  





of channel regulation, likely at the transcriptional level.  Cha et al (2004b) saw a similar decrease 
in ICaL and Ito, and also observed an increase in inward rectifier potassium current (IK1, active in 
late repolarization) in a canine model of AF with or without congestive heart failure.  These 
decreases in inward ICaL and increases in IK1 contribute to a shortening of the APD.  Some animal 
model studies have also observed a decrease in the depolarizing sodium current INa, which could 
possibly contribute to a slowing of the atrial conductance velocity (Gaspo et al, 1997, Yagi et al, 
2002).  Analysis of gene expression profiles of atrial tissue from human valve disease patients in 
sinus rhythm or with AF confirmed some of these animal model findings.  AF was associated 
with an increased expression of Kir2.1 mRNA and protein, with a corresponding increase in IK1 
current density.  Cav1.2 expression was lower in valve disease patients, regardless of heart 
rhythm, than non-valve disease patients; however corresponding  ICaL current density was 
significantly lower in patients with AF (Gaborit et al, 2005).   
 The decrease in ICaL is thought to be an adaptive response to increased calcium loading.  
As atrial firing rates increase in isolated atrial myocytes, the intracellular concentration of 
calcium increases with every action potential, ultimately resulting in poor contractility (Sun et al, 
2001).  Downregulation of ICaL decreases calcium loading, but also contributes to a decrease in 
the action potential duration, thus promoting AF.  Other calcium handling dysfunctions have also 
been implicated with AF; hyperphosphorylation of the ryanodine receptor was seen in atrial 
tissue from rapid-paced AF canines, and from human patients with AF.  This resulted in calcium 
"leak" from the sarcoplasmic reticulum of canine atrial myocytes, which likely results in 
decreased excitation-contraction coupling and decreased contractility (Vest et al, 2005).  Other 
components of the calcium handling machinery have been shown to be either hyper- or 





heterogeneity of kinase and phosphatase activity (El-Armouche et al, 2006), resulting in further 
calcium leak from the sarcoplasimc reticulum and impaired contractility. 
 Changes in cell conductivity through gap junctions are also likely involved in atrial 
remodeling.  The predominant connexin proteins forming gap junctions in atria are connexin 
(Cx) 40 and Cx43.  The changes observed in connexin expression and distribution are not 
consistent across models, but differences between sinus rhythm and AF are often observed to 
some degree (reviewed van der Velden and Jongsma, 2002).  No changes in Cx43 were observed 
in the goat rapid atrial pacing model of AF, but the distribution of Cx40 was heterogeneous after 
sustained AF, and with increased time in the arrhythmia the expression of Cx40 at the 
intercalated disks continued to decrease (van der Velden et al, 2000).  However, in a canine 
model of rapid atrial pacing AF, Cx43 expression increased (Elvan et al, 1997).  The expression 
of Cx40 was also shown to be lower in human patients with AF, and expression decreases with 
increasing disease severity (Kanagaratnam et al, 2004).  Additionally, a polymorphism in the 
Cx40 promoter region is associated with an increased susceptibility to AF and increased 
heterogeneity of atrial refractoriness in human patients (Firouzi et al, 2004), further implicating 
gap junction dysfunction with AF. 
 Decreases in atrial contraction due to electrical remodeling can then act as a stimulus for 
structural remodeling, which takes place over a longer timeframe of weeks to months after 
initiation of an arrhythmia.  Structural remodeling results in slowed and heterogeneous impulse 
conduction, facilitating reentry without causing further changes to the action potential.  
Structural changes tend to be far less reversible than electrical remodeling, and to persist even 





atrial pacing-induced AF, sustained AF led to atrial dilation, myocyte hypertrophy, loss of 
sarcomere organization (myolysis), and mitochondrial abnormalities (Morillo et al, 1995).  
Similar changes were seen in the goat (Ausma, 1997).  Although fibrosis is often not seen in 
animal models of AF induced by rapid atrial pacing, it is strongly associated with the human 
disease, either as a risk factor or a consequence (Boldt et al, 2004; Frustaci et al, 1997), and has 
been linked to atrial fibrillation and conduction heterogeneity in a canine model of chronic heart 
failure (Cha et al, 2004a).  The renin-angiotensin system, the pro-fibrotic cytokine TGF-β1, and 
inflammatory signaling all contribute to the proliferation of fibroblasts and reorganization of the 
extracellular matrix (reviewed by Aldhoon et al, 2010).  
 
Modulating factors 
 The autonomic nervous system can regulate atrial refractoriness and calcium handling, 
and therefore arrhythmogenicity.  Increased vagal tone decreases the action potential duration 
and refractory period (Prystowsky et al, 1983) and depresses intra-atria conduction, and has been 
shown to contribute to block and reentry in frog atrial fibers (Rosenshtraukh et al, 1991).  These 
changes to the action potential and atrial conduction are at least in part through activation of the 
acetylcholine-activated inward rectifying potassium current (IKACh) (Schuessler et al, 1992) and 
inhibition of calcium currents through activation of muscarinic acetylcholine receptors 
(Wickman and Clapham, 1995).  Parasympathetic modulation tends to be heterogeneous, due to 
the uneven distribution of parasympathetic nerve endings and muscarinic acetylcholine receptors 
(Arora et al, 2008).  Stimulation of the vagus nerve or of cardiac ganglionated plexi has been 





vagal activity in the development of the human disease is not clear, various studies have found 
an association between increased vagal tone, as indicated by heart rate variability, and 
paroxysmal AF in patients with "lone" AF (without underlying cardiovascular disease); however, 
this association is not consistent across studies, and  investigations into the effectiveness of vagal 
denervation as an antiarrhythmic strategy are inconclusive (reviewed by Zhang and Mazgalev, 
2011).  Sympathetic modulation is more complex.   β-Adrenergic receptor activation increases 
ICaL, ultra-rapid outward potassium current (IKur), slow delayed rectifier potassium current (IKs), 
and IKACh.  On the other hand, α-adrenergic stimulation inhibits Ito, IK1, and IKACh (reviewed by 
Schotten et al, 2011), with the net effect being a prolonged action potential plateau without a net 
increase in the total APD, and increased Ca2+ loading. 
 Inflammation is also highly associated with the onset and progression of AF.  Biopsies 
from patients with AF show greater infiltration of inflammatory cells into the atrial myocardium 
relative to patients in sinus rhythm (Frustaci et al, 1997).  Furthermore, patients with persistent 
AF have a higher level of systemic C-reactive protein than patients with paroxysmal AF, 
suggesting that increased inflammation is associated with increased disease burden, and may 
play a role in the persistence of AF (Chung et al, 2001).  Inflammation contributes to fibrosis 
through the release of oxidative products from leukocytes resulting in cell damage (Entman and 
Smith, 1994).  Furthermore, there is a clear association between inflammation and the onset of 






Human disease and animal models 
 AF as a chronic human disease is subdivided into paroxysmal AF (self-terminating 
episodes interspersed with periods of normal sinus rhythm, thought to be due to ectopic activity 
without an arrhythmogenic substrate to sustain it), persistent AF (non-self-terminating, but sinus 
rhythm can be restored with cardioversion), and permanent AF (cannot be converted to sinus 
rhythm).  Once initiated, electrical and structural remodeling takes place which reinforce the 
arrhythmia, so that “AF begets AF” (Wijffels 1995).  In this way, patients with paroxysmal AF 
often progress to longer non-terminating episodes (Allessie et al, 2001); it is estimated that 
within 3-4 years, 20% of patients with paroxysmal AF will progress to the permanent disease 
(Greenlee and Vidaillet, 2005).  AF is often co-morbid with significant cardiovascular disease, 
including congestive heart failure, coronary artery disease and myocardial ischemia, and mitral 
valve disease and volume overload (reviewed by Nattel et al, 2005). 
 This chronic AF can be modeled in animals through tachycardic pacing of the atria.  
Sustained rapid atrial pacing induces remodeling and promotes the maintenance of the 
arrhythmia, even in the absence of continued pacing (Morillo et al, 1995; Yagi et al, 2002).  This 
model results in shortened refractory periods and increased heterogeneity of refractoriness, 
similar to the human disease (Fareh et al, 1998), and promotes the formation of multiple 
reentrant circuits (Gaspo et al, 1997). 
 One acute manifestation of AF, peri-operative atrial fibrillation (POAF) is one of the 
most common complications following cardiothoracic surgery, affecting as many as 30-60% of 
patients in the 2-3 days following surgery (reviewed by Hogue et al, 2005).  Although the exact 





not known, Hogue et al (1998) found that the balance of sympathetic and vagal regulation of the 
heart rate, as indicated by the heart rate variability, was altered in human patients who went on to 
develop POAF.  Furthermore, inflammation, due to direct myocardial injury and to ischemic 
damage from cardiopulmonary bypass, is thought to contribute to the etiology of the disease, 
with the peak incidence of POAF coinciding with the peak levels of circulating C reactive 
protein, interleukins-1 and 6, complement components, and leukocytes (reviewed by Baker and 
White, 2007).  Ishii et al (2005) found a positive correlation between neutrophil infiltration, 
inhomogeneity of atrial conductance, and subsequent AF in dogs post-atriotomy.  Anti-
inflammatory steroid treatment before surgery was able to reduce the conduction irregularities 
and the incidence of AF.  Similarly, Fontes et al (2005) found that human patients that developed 
AF after coronary artery bypass grafting or cardiopulmonary bypass had a larger increase in 
systemic levels of monocytes and neutrophils than patients who remained in normal sinus 
rhythm (NSR).  Analysis of several placebo-controlled studies found that treatment with anti-
inflammatory corticosteroids resulted in a significant reduction in the incidence of POAF after 
cardiac surgery, although the risk of complications increased with high steroid doses (Marik and 
Fromm, 2009). 
 
Neutrophils in inflammation  
 Neutrophils are polynucleated leukocytes that are involved in the early responses of the 
innate immune system.  In the post-capillary venules, neutrophils encounter markers of cell 
injury, such as histamine, thrombin, activated complement, leukotrienes, or free radicals, 





stimulation by distress markers on the endothelial surface results in a firm adherence of 
neutrophils to the vessel wall, and neutrophils become activated, changing from spherical to 
flattened in shape.  The activated neutrophils can then transmigrate between enthothelial cells 
across a chemotactic gradient of stimuli such as platelet-activating factor (PAF), leukotriene B4, 
and interleukin-8, past the basement membrane, and into the surrounding interstitial tissue in a 
process called extravasation (reviewed by Albelda et al, 1994; Frangogiannis et al, 2002).  
 Neutrophils are known to contribute to ischemic tissue damage, by blocking the 
microvasculature during vessel adherence and by releasing autacoids that promote 
vasoconstriction and platelet aggregation.  They also cause direct damage to the tissue (reviewed 
by Entman and Smith, 1994; Frangogiannis et al, 2002) by adhering to cells and releasing 
oxidative and proteolytic enzymes.  One of these oxidative enyzmes, myeloperoxidase, has been 
linked to fibrosis in a mouse model, and is elevated in the plasma of patients who develop 
paroxysmal AF, and in the atrial myocardium of patients with chronic AF (Rudolph et al, 2010).  
Neutrophils also release, and induce the injured tissue to further release, cytokines to recruit 
additional inflammatory cells. 
 Activated neutrophils are known to be arrhythmogenic in isolated ventricular myocytes 
(Hoffman et al, 1997; Ward et al, 2006), and in isolated hearts (Dhein et al, 1995).  They are also 
associated with the development of peri-operative AF in the whole animal and in patients, as 
discussed above (Ishii et al, 2005; Fontes et al, 2005).  One of the inflammatory mediators 
released from neutrophils that contributes to arrhythmogenisity is the phospholipid platelet-







 PAF is a glycerophosphorylcholine that plays a physiological role in inflammation, as 
well as apoptosis, angiogenesis, and long-term potentiation (reviewed by Stafforini et al, 2003).  
PAF is synthesized by stimulated leukocytes and endothelial cells and once released interacts 
with the widely expressed PAF receptor (PAFR), which is a seven-transmembrane receptor 
coupled to Gαq/11 or several other G-proteins.  Through these G-proteins, the PAFR is able to 
stimulate various signal transduction cascades, including stimulation of PLC/PKC and p38 MAP 
kinase pathways, in various cell types.   
 It has long been known that PAF induces repolarization abnormalities in ventricular 
myocytes, and arrhythmias in isolated guinea pig, rabbit, or rat hearts, although the in vivo 
effects show significant species variability.  PAF infusion in vivo results in decreased cardiac 
output through a combination of direct negative ionotropic effects and decreased venous return 
(Montrucchio et al, 2000).  Infusion of PAF in the isolated guinea pig heart causes a decrease in 
contractile force and coronary flow in a concentration-dependent manner, and also induces 
conduction arrhythmias (Riedel et al, 1987).  In isolated ventricular myocytes, PAF causes an 
inhibition of IK1 (Wahler et al, 1990) and activation of L-type and T-type calcium currents 
(Bkaily, 1996).  Treatment with PAFR antagonists is antiarrhythmic in rat and canine models of 
ischemia/reperfusion injury (reviewed by Montrucchio et al, 2000).  The action potential 
duration and incidence of early after depolarizations increase in a dose-dependent manner after 
addition of PAF to isolated canine ventricular myocytes (Hoffman et al 1996).  Hoffman et al 
(1997) went on to demonstrate that accumulation and activation of neutrophils could result in 





 It has since been shown in our lab that carbamyl-PAF (C-PAF), a stable nonhydrolyzable 
analogue of PAF, induces repolarization abnormalities through a PKCε-dependent inhibition of 
current through the two-pore domain channel TASK-1 in isolated mouse ventricular myocytes 
(Barbuti et al 2002, Besana et al 2004). 
 
Two-pore domain potassium channels 
 The two-pore domain potassium channels (K2P) are a recently characterized family of K+ 
selective channels.  They are not voltage-gated or time-dependent, and contribute to the “leak” or 
background currents that help set the membrane potential and contribute to membrane 
repolarization.  They form functional dimers, and each subunit is composed of four membrane-
spanning units, two pore-forming units, a relatively short cytoplasmic N-terminal and a longer C-
terminal tail.  The C-terminus contains numerous regulatory sites, including phosphorylation 
sites and lipid-binding domains.  These channels are insensitive to the common K+ channel 
blockers (TEA, 4AP, Ba2+), which can be used to pharmacologically isolate the K2P currents 
from these other potassium currents for measurements in native tissue.  They are widely 
expressed in excitable tissue, and have an established role in modulating neuronal excitability 
(reviewed by Kim, 2005). 
 TASK-1 is an openly rectifying channel with a current-voltage relation that is linear in 
the presence of symmetrical K+ and outwardly rectifying in physiological solution.  It is acid 
sensitive (Duprat, 1997), and is blocked by the endocannabinoid, anandamide and its 
nonhydrolyzable analogue, methanandamide (Maingret 2001).  This inhibition allows 





after methanandamide exposure with appropriate solutions and voltage clamp protocols.  TASK-
1 is expressed in the brain, heart, carotid body, adrenal gland, GI smooth muscle, and several 
other tissues (reviewed by Kim, 2005).  Members of the TASK family are known to be inhibited 
downstream of G-protein signaling in the brain (reviewed by Mathie 2007), by PIP2 hydrolysis 
(Lopes et al, 2005) and possibly directly by Gαq subunits (Chen et al, 2006).  TASK-1 has also 
been shown to be activated downstream of activation of the nitric oxide-cGMP-PKG pathway by 
decreasing the binding affinity for inhibitory protons (Toyoda et al, 2010). 
 
TASK-1 inhibition downstream of C-PAF signaling 
 There is an expanding body of work describing the importance of K2P channels in the 
cardiovascular system (reviewed by Gurney and Manoury, 2008).  In Drosophila, the K2P 
channel ORK1 helps control the heart rate; inactivation of the channel resulted in a faster heart 
rate, while overexpression resulted in a hyperpolarized myocyte resting potential and heart block 
(Lalevée et al, 2006).  In rat atrial myocytes, the K2P channels TASK-1, TREK-1 and TWIK-1 
are present in the atrium at the RNA level (Liu and Saint, 2004), and expression of TASK-1 
(Jones et al, 2002) and TREK-1 (Terrenoire et al, 2001) at the protein level have been confirmed.  
TASK-1 and TWIK-1 are also present in human myocardium, with higher mRNA levels in the 
atria compared to the ventricles (Ellinghaus et al, 2005). 
 Data from the TASK-1 knockout mouse suggest a role for TASK-1 in repolarization of 
the action potential.  In the TASK-1-deficient transgenic mouse, animals displayed a faster 
resting heart rate and prolongation of the rate-corrected QT interval as well as a broadened QRS 





myocytes, or from ventricular free wall recordings of isolated hearts (Donner et al, 2011; Decher 
et al, 2011).  Putzke et al (2007) confirmed that pharmacological inhibition of TASK-1 similarly 
increased the APD in rat ventricular myocytes.   
 Furthermore, previous work in our lab has identified TASK-1 as a C-PAF-sensitive 
current in mouse ventricular myocytes (Barbuti 2002).  Inhibition of TASK-1 by 
methanandamide was found to be sufficient to cause prolongation of the APD and induce EADs, 
mimicking the effect of C-PAF or activated neutrophils in isolated canine ventricular myocytes.  
This data suggested that inhibition of TASK-1 could contribute to the known pro-arrhythmic 
effects of activated neutrophils and PAF.  Since neutrophils are activated in early inflammation, 
and have been shown to be associated with the initiation of POAF, it is possible that inhibition of 
TASK-1 could be associated with inflammation and the initiation of AF.  
 Besana et al (2004) determined that the C-PAF-dependent TASK-1 inhibition required 
PKCε, and that activation of the kinase was necessary and sufficient for C-PAF-dependent action 
potential abnormalities and TASK-1 inhibition in mouse ventricular myocytes.  Interestingly, 
PKCε has been shown to be upregulated in human AF (Voigt et al, 2007).   
 The PKC consensus site threonine-381 (T381) in the mouse TASK-1 (mTASK-1) C-
terminus was implicated as the site targeted downstream of PAFR signaling; mutation of T381 to 
nonphosphorylatable alanine  prevented PKC- and C-PAF- dependent mTASK-1 channel 
inhibition in CHO cells (Besana et al, 2004).  However, the sequence of the rodent TASK-1 C-
terminus differs from the human and canine.  Instead of one high-scoring PKC consensus site 
there are at least two, at serine-358 (S358) and threonine-383 (T383) of human TASK-1 





sequences is shown below, with the known mouse phosphorylation site highlighted and with 
other predicted PKC phosphorylation sites underlined, including the high-scoring S358 and T383 
in the human sequence (corresponding to S359 and T384 in the canine sequence).  
Phosphorylation of the terminal SSV by PKA has been shown to be required for 14-3-3 binding 
to TASK-1 channel, and subsequent trafficking from the endoplasmic reticulum (Mant et al, 
2011; O'Kelly et al, 2002), and is likely not involved in dynamic PKC-dependent channel 
regulation of the channel at the membrane. 
 
Mouse TASK-1  361 SPGGGGRYSDTPSHPCLCSGTQRSAISSVSTGLHSLAAFRGLMKRRSSV 409  
Human TASK-1  346 SPGGGGRYSDTPSRRCLCSGAPRSAISSVSTGLHSLSTFRGLMKRRSSV 394 
  Dog TASK-1  347 SPGGGGRYSDTPSHRCLCSGAQRSAISSVSTGLHSLSTFRGLMKRRSSV 395 
 
In order to investigate TASK-1 phosphorylation in a canine disease model or in human patients, 




 The general questions of interest in this thesis involve the inhibitory phosphorylation of 
TASK-1 downstream of inflammatory signaling, and its role in atrial fibrillation.  The specific 





1. What is the hTASK-1 phosphorylation site downstream of C-PAF and PKCε 
signaling? 
2. Is there a relationship between inhibitory phosphorylation of TASK-1, neutrophil 
 influx into the myocardium, and the initiation of acute atrial fibrillation? 
3. Is there a relationship between inhibitory phosphorylation of TASK-1, neutrophil 





CHAPTER 2: METHODS 
 
Immunoprecipitation of TASK-1 
 Native TASK-1 protein was immunoprecipatated from dog right atrium using the Seize-
X Protein A Immunoprecipitation Kit (Pierce), following a modification of the methods of 
Olschewski et al (Circ Res 2006).  125 µg of a rabbit polyclonal antibody specific for the 
252EDEKRDAEHRALLTRNGQ269 epitope of hTASK-1 (which shares 100% homology with the 
canine sequence, and 94% homology with the rodent sequence at this epitope) was crosslinked to 
100 µl packed protein A agarose.  Approximately 300 mg frozen canine atrial tissue was 
homogenized in 1 ml buffer containing 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 2 mM EGTA, 2 
mM EDTA, 0.1 mM PMSF, 1 ng/ml apoprotinin, 1 ng/ml leupeptin, 0.1 µM pepstatin, 1 µg/ml 
benzamidine, 1 mM activated sodium orthovanadate, 5 mM NaF and 1% Triton X-100.  
Incompletely homogenized debris was removed by centrifugation at 3000g, and the protein 
concentration of the sample measured by a modification to the method of Lowry (Peterson et al 
1977).  500 µg of homogenate was diluted to 1 mg/ml in  homogenization buffer and phosphate-
buffed saline (1/1, v/v) and allowed to interact with the crosslinked antibody in Handee spin cup 
columns (Pierce) for 16 h at 4°C.  The resin was recovered by centrifuation at 3000g, after which 
the buffer containing unbound protein ("depleted flow-through") was collected. The resin was 
washed twice with 500 µl homogenization buffer, once with homogenization buffer 
supplemented with an additional 375 mM NaCl for increased ionic strength, and twice more with 
normal homogenization buffer.  Protein was eluted from the antibody resin three times in 190 µL 





eluate. At each step, 10% of the volume was reserved for analysis.  Samples were boiled in 
Laemmli sample buffer, loaded onto 10% polyacrylamide tris-glycine gels, and run and 
transferred to nitrocellulose by standard protocols.  Membranes were blocked in tris-buffered 
saline (TBS, pH 7.4) with 0.1% Tween-20 and 5% nonfat milk, and TASK-1 was visualized by 
incubation with the same antibody used for immunoprecipitation (2.8 µg/ml in blocking solution) 
followed by incubation with horse radish peroxidase-conjugated anti-rabbit antibody and 
chemiluminescent substrate (Agilent).  Membranes were stripped with Restore western blot 
stripping buffer (Thermo Fisher) and reblocked in TBS with 0.1% Tween-20 and 2% bovine 
serum albumin, 1% PEG-3350, and 1% PVP-10.  Phosphorylated serine or threonine was 
detected by incubation with a mouse monoclonal anti-phospho serine or anti-phospho threonine 
antibody (Biomol, 0.02 µg/ml in blocking solution). 
 Since protein aggregated during the immunoprecipitation, additional 
immunoprecipitations were attempted under different conditions.  The procedure was repeated 
by binding crude membranes to the antibody resin instead of a total lysate.  Right atrium was 
thawed in the above homogenization buffer without detergent, homogenized as above, and debris 
was pelleted at 3000g.  Then a membrane fraction was pelleted by ultracentrifugation of the 
previous supernatant at 160000g for 1 h.  Membranes were resuspended in homogenization 
buffer with 1% triton-x100, and bound to antibody resin as above.  Alternate experiments were 
also performed using different detergent conditions (0.1% triton-x100 or 0.8% digitonin instead 
of 1% triton-x100), different binding conditions (2 h at 4°C or room temperature instead of 16 h 
at 4°C), different elution conditions (0.1 M glycine-NaOH pH 10.0 or 200 µM antigenic peptide, 





detected in immunoblots of homogenized tissue not subjected to immunoprecipitation protocols, 
all of the attempts at immunoprecipitation resulted in sample aggregation, and none of the 
alternate protocols resulted in a better yield than the original protocol. 
 Additional experiments were performed to purify heterologously expressed hTASK-1 
from CHO cells by inserting a FLAG tag and immunoprecipitating with an antibody that 
recognized this epitope.  A DYKDDDK FLAG sequence was inserted into the N-terminus of 
hTASK-1 in the pDC-IE vector using the PCR-based Quick Change kit (Agilent), as per the 
manufacturer's protocol.  The insertion was performed in two steps, using the primers 5'-
GCCCTTCGATGGATTACAAGGAAAGCGGCAGAACGTGCG-3' and 5'-
CGCACGTTCTGCCGCTTTCCTTGTAATCCATCGAAGGGC-3', followed by the primers 5'-
CGATGGATTACAAGGATGACGACGATAAGCGGCAGAACG-3' and 5'-
CGTTCTGCCGCTTATCGTCGTCATCCTTGTAATCCATCG-3'.  The gene was sequenced to 
ensure that the tag was properly inserted and that there were no unintended changes. 
 CHO cells were grown in F12 medium with glutamax and 10% FBS.  Cells were plated 
at 50-70% confluence, and the next day were transfected with Flag-hTASK-1/pDC-IE using the 
Genejammer transfection reagent (Agilent).  After 48 h, cells were scraped into homogenization 
buffer (see above), sonicated, and the debris removed after centrifugation at 3000g.  The 
homogenate from approximately 1.5x106 cells was added to 20 µl of packed of anti-FLAG M2 
affinity gel resin (Sigma), and bound at 4°C for 16 h.  The mixture was centrifuged at 8000g to 
recover the resin, and the depleted supernatant was removed.  The resin was washed with 
homogenization buffer, and bound proteins were eluted with 100 µl of 300 ng/ml purified FLAG 





Laemmli sample buffer for analysis, and at the end of the experiment, the resin was similarly 
boiled in sample buffer.  Samples were loaded onto 10% polyacrylamide tris-glycine gels, and 
gels were run and protein transferred to nitrocellulose membranes by standard protocols. 
 Since the protein aggregated considerably during immunoprecipitation, as detected by the 
presence of TASK-1 immunoreactivity in the antibody resin and as a high molecular weight 
smear in the eluate, additional experiments were performed using alternative binding buffers: 
high salt (300 mM NaCl), 10% glycerol, or high salt plus 10% glycerol was added to the 
homogenization buffer and used for affinity resin binding, washing, and elution.  Each alternate 
buffer resulted in similar protein aggregation in the affinity resin. 
 
Generation of hTASK-1 C-terminus GST fusion proteins 
 The 150-residue carboxyl-terminus of hTASK-1 (residues L244 to V394) was amplified 
from the pIRES2-EGFP vector (Clontech) by PCR, using primers to insert a BamHI restriction 
site upstream of the target sequence,  and a XhoI restriction site downstream of the amplified 
fragment (upstream 5'-CAACCTCGTGGTGGGATCCCTGCGCTTCATG-3'; downstream 5'-
CCTCGGGGCAGCTCGAGCCACGGAGCTCC-3').  100 ng of hTASK-1/pIRES2-EGPF 
template was combined with 300 ng of each primer according to the Quickchange II protocol 
(Stratagene), and elongated for 50 cycles.  The resulting 460-bp fragment was resolved by 
agarose gel electrophoresis, purified from the gel (Qiagen), and 2 µg was digested with 10U 
BamHI and 10U XhoI in 30 µl for 2 h 37°C.  In parallel, 2 µg of pGEX4T3 GST host plasmid 
(Amersham; kind gift of Dr. R Kass) was digested, and then treated with 4U of alkaline 





digested host and insert fragments were gel purified, combined in a 1:1 molar ratio, and ligated 
(Roche).  DNA was transformed into E. coli, amplified, and successful integration of the insert 
was confirmed by restriction digest, PCR, and sequencing analysis. 
 Additional GST-fusion proteins were made, as above, by amplifying only the distal 134 
residues (H260-V394) of the carboxyl-terminus, using the upstream BamHI insertion primer 5'-
CGACGCCGAGGGATCCCACCGCGCGCTG-3', or the distal 44 residues of the carboxyl-
terminus (G350-V394), using the upstream BamHI insertion primer 5'-
CTCGTCGCCGGGAGGGGGCGGCCGCTACAG-3'.  Respective constructs were analyzed for 
successful integration of the 390-bp or 120-bp insert. 
 The full-length hTASK-1 C-terminus GST fusion protein coding sequence was also 
cloned back into the mammalian expression vector pIRES2-EGFP, by insertion of the upstream 
BglII site and downstream EcoRI site into the construct in pGEX4T3, using PCR amplification 
followed by digestion and ligation, as described above (upstream 5'-
GTGGAATTGTGAGCGGATAACAATTTCACACAAGATCTGTAGTCATGTCCCCTATAC
TAG-3'; downstream 5'-CCGAAACGCGCGAGGCAGAATTCAGTCAGTCACGATGC-3'). 
 
Mutations of putative PKC phosphorylation sites 
 Mutations in the putative PKC phosphorylation sites were created using the PCR-based 
Quick Change II kit (Agilent) to mutate serine 358 or threonine 383 to nonphosphorylatable 






GCTGCACAGGCAGCGTCGCGCGGGCGTGTCGCTGTA-3’ for S358A, and 5’-
CTGCACAGCCTGTCCGCCTTCCGCGGCCTCATGAAG-3’ and 5’-
CTTCATGAGGCCGCGGAAGGCGGACAGGCTGTGCAG-3’ for T383A.  Mutants were 
created in the full-length hTASK-1 sequence in pDC-IE mammalian expression vector, as well 
as in the distal 44-residue C-terminus GST fusion protein in the pGEX4T3 bacterial expression 
vector. 
 
Purification of GST fusion proteins 
 The hTASK-1 C-terminus-GST fusion construct was transformed into BL21-Gold E. coli 
cells (Agilent), and expression was induced with 0.1 mM IPTG.  The fusion proteins were 
purified using the B-Per GST fusion protein purification kit (Pierce), according to the 
manufacturers' protocol.  Purification steps were tracked by running 0.4% of the total volume of 
each binding, washing, and elution step on a 12% polyacrylamide tris-glycine gel, transferring to 
nitrocellulose, and immunoblotting with an antibody against GST (Santa Cruz). 
 The full-length hTASK-1 C-terminus fusion protein (L244-V394) was insoluble when 
expressed in E. coli, and localized to inclusion bodies (Fig 4a).  Changing to high-salt (300 mM 
NaCl) lysis buffer and reducing with DTT (5 mM) had no effect, nor did switching to a different 
manufacturer's Glutathione-Sepharose B (GE Amersham).  After denaturing solubilized 
inclusion bodies in 8 M Urea and 5 mM DTT, dialysis in various buffers (0.2 or 1 M Urea, 0 or 5 
mM EDTA, 5 or 20 mM L-arginine, 1:0.5 or 1.25:0.25 mM GSH:GSSG, pH 8.0 or 9.0) was not 
able to successfully refold the protein.  Successful refolding was measured by assaying the 





340nm (Liu et al, 2007).  This construct was also insoluble when transfected into cultured CHO 
cells using the Genejammer transfection reagent (Strategene/Agilent), even after gentle 
denaturation of cell lysates with 0.5 M Urea. 
 The shortest distal 45-residue hTASK-1 C-terminus GST fusion protein construct (G350-
V394), and fusion protein constructs with S358A and T383A mutations, were soluble and 
successfully expressed and purified from bacterial cells.  Constructs were transformed into BL21 
E. coli cells (Agilent) grown to an O.D. at 600 nm of approximately 0.6, and expression was 
induced with 0.1 mM IPTG.  Cells were pelleted and sonicated into PBS containing 1% Triton 
X100 and protease inhibitor cocktail.  Solubilized protein was loaded onto immobilized 
glutathione columns, washed in solubilization buffer, and eluted into TBS pH 8.5 containing 
0.1% Triton X100 and 10 mM GSH.  Eluted protein was concentrated by column ultrafiltration 
(Vivaspin, 10 kDa molecular weight cutoff), and the buffer was readjusted to 10 mM TrisHCl 
pH 7.4. 
 
In vitro kinase assay 
 4 µg of GST or purified distal 45-residue hTASK-1 C-terminus GST fusion protein (wild 
type, S358A, or T383A) were combined with 0.1 µg of recombinant PKCε (kind gift of Dr. 
Susan Steinberg) in the presence of phosphotidylserine (16.7 µg), phosphomolybdic acid (PMA, 
160 µM), and adenosine triphosphate (ATP, 66 µM) containing 3 µCi of [γ−32P]ATP tracer 
(Perkin Elmer).  Reactions were incubated for 30 min at 30°C while mixing at 120 rpm, in a 





EDTA, 0.5 mM EGTA, 0.175 mM DTT, and 3% glycerol in a final volume of 80 µl.  Reactions 
were stopped by the addition of one third volume 4X Laemmli sample buffer.  Samples were 
boiled and resolved by SDS-PAGE on a 12% tris-tricine gel, and transferred to nitrocellulose by 
standard protocols.  The nitrocellulose membrane was exposed to x-ray film for 3 h to visualize 
radioactivity, and the radioactive bands were excised from the membrane.  After excision, the 
blot was re-exposed to x-ray film to verify complete removal of the radiolabeled band. 
 
Peptide mapping 
 Excised membrane bands were blocked with 0.5% PVP-40 in 100 mM acetic acid for 30 
min at 37°C, washed, and minced into 1 mm x 1mm fragments.  Membranes were washed in 
water, and protein on the membranes was digested with 5 µg sequencing grade trypsin in 50 mM 
NH4HCO3 at 37°C for 16 h. Digested peptides were eluted from the membrane by sonication, 
dried, and reconstituted in 0.1% TFA. The digest was fractionated by reversed phase high-
performance liquid chromatography (RP-HPLC) on a HP1090 liquid chromatograph using a 
Vydac semimicro C18 column (2.1 x 250 mm).  Peptides were eluted with a linear gradient from 
0.1% TFA in water to 0.1% TFA in acetonitrile over 140 min at a flow rate of 1 ml/min.  Elution 







Identification of phosphorylation sites by mass spectrometry 
 Analysis was performed by the Protein Chemistry core at Columbia University Medical 
Center.  Briefly, the wild-type distal 45-residue hTASK-1 GST construct was phosphorylated by 
PKCε as described above, without the addition of [γ−32P]ATP tracer, and reactions were resolved 
by SDS-PAGE.  Bands were excised from Coomassie brilliant blue-stained polyacrylamide gels, 
and submitted to the core facility.  Protein was trypsin-digested and the peptides were resolved 
by liquid chromatography coupled to electrospray ionization (ESI-LC).  The peptides were 
identified by tandem mass spectrometry (MS/MS) before and after collision-induced 
dissociation.  The fragmentation patterns of the peptides were compared to the predicted 
fragment ions using the MASCOT peptide mass analysis program to search for post-translational 
modifications.  This ESI-LC-MS/MS analysis detects phosphorylation of threonine by 
identification of dehydroamino-2-butyric acid in place of threonine (MW=83.1 Da). 
 
Measurement of hTASK-1 current in CHO cells 
 pDC-IE vector encoding the full length wild-type, S358A, or T383A hTASK-1 and GFP 
was transfected into CHO cells using Genejammer transfection reagent (Agilent) according to 
the manufacturer's protocol.  After 48 h, cells were washed with PBS and resuspended in 
enzyme-free cell dissociation buffer (Invitrogen) and plated onto glass coverslips.  The cells 
were superfused at room temperature with a Tyrode’s solution containing (in mM): NaCl 140, 
KCl 5.4, CaCl2 1, MgCl2 1, HEPES 5, glucose 10, adjusted to pH 7.4 and with an osmolarity 
~298 mOsm, or with the above solution containing 185 nM C-PAF or 100 nM PMA.  Current 





configuration using borosilicate glass pipettes with a tip resistance between 4-6 MΩ and filled 
with a solution containing (in mM): aspartic acid 130, KOH 146, NaCl 10, CaCl2 2, EGTA 5, 
HEPES 10, MgATP 2, adjusted to pH 7.2 and osmolarity ~ 295 mOsm.  Cells expressing GFP 
(20-30% of cells) were patched, and all of those contained TASK-1 current.  Recordings were 
made before and after the addition of 185 nM C-PAF or 100 nM PMA to the superfusate, and a 
C-PAF- or PMA-sensitive difference current was calculated from the traces. 
 A PKCε inhibitor peptide (εV1-2: EAVSLKPT) and a scrambled control peptide 
(LSETKPAV) were synthesized by the Columbia University Medical Center Protein Core 
facility and diluted to 100nM in pipette solution (Besana et al, 2004; Johnson et al, 1996). In 
some experiments, peptides were added to the patch pipette and allowed to dialyze into the cell 
for 8-10 min before measuring the C-PAF-sensitive difference current as above. 
 The voltage clamp protocols were generated using Clampex 8.0 software applied by 
means of an Axopatch 200-B and a Digidata 1200 interface (Axon Instruments).  Current signals 
were filtered at 2 KHz and acquired at 500 Hz.  All recordings were corrected for the junctional 
potential (-9.8 mV). 
 
Generation and validation of a pT383 phosphorylation site-specific antibody 
 A custom phosphorylation site-specific antibody (PSSA) was raised in rabbits against 
residues 376-389 of human TASK-1, phosphorylated at T383 (Yenzyme).  The antibody was 
affinity purified and its affinity for the phosphorylated versus non-phosphorylated peptide was 





500 ng of purified wild type or T383A GST/hTASK-1 C-terminus construct, with or without 
PKCε phosphorylation, or 500 ng of phosphorylated wild type construct with or without 
treatment with 1.1 U Acid Phosphatase (Sigma) on a 12.5% SDS polyacrylamide gel, and 
transferring the proteins to nitrocellulose according to standard protocols.  The phosphorylated 
TASK-1 band was visualized by incubation with the custom antibody, followed by incubation 
with a sheep anti-rabbit antibody coupled to horseradish peroxidase (GE Amersham), 
development with PicoWest ECL substrate (Pierce), and exposure to x-ray film.  Blots were 
stripped and reprobed with an antibody against GST (Santacruz) to verify equal loading. 
 
Expression of hTASK-1 in cell lines and treatment with C-PAF 
 pDC-IE containing the full length wild-type or T383A hTASK-1 and GFP were 
transfected into CHO cells using Genejammer transfection reagent (Agilent) according to the 
manufacturer's protocol.  Cells were treated 48 h following transfection, and 3-16 h before 
treatment, media was changed to Opti-MEM serum-free medium (Invitrogen).  Cells were 
incubated 20 min in 1 µM C-PAF or in Opti-MEM vehicle, and then the medium was removed 
and cells were scraped into a detergent-free homogenization buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1 mM EGTA, 250 mM sucrose, 0.1 mM PMSF, 1 ng/ml apoprotinin, 1 ng/ml 
leupeptin, 0.1 µM pepstatin, 1 µg/ml benzamidine, 1 mM activated sodium orthovanadate, 5 mM 
NaF).   Cells were disrupted by sonication, and separated into crude membrane and cytosol 
fractions by ultracentrifugation at 160000g for 1h at 4°C.  Membrane pellets were resuspended in 
homogenization buffer containing 1% Triton X100.   Total protein content from each sample was 





amounts of protein were prepared in laemmli sample buffer, boiled for 10 min, and loaded onto 
and run on duplicate 10% polyacrylamide tris-glycine gels, and transferred to nitrocellulose 
according to standard protocols.  Membranes were blotted against total TASK-1 using a rabbit 
polyclonal antibody raised against the 252EDEKRDAEHRALLTRNGQ269 epitope of the 
hTASK-1 protein (BIOMOL; 1.5 µg/ml), or phosphorylated TASK-1 by incubation with the 
pT383 phosphorylation site-specific antibody described above (10 µg/ml), followed by 
incubation with an HRP-conjugated anti-rabbit secondary antibody followed by 
chemiluminescent substrate (Pierce West Pico). 
 Transfection, treatment, and sample preparation procedures were repeated in other cell 
lines.  TSA-201 cells (HEK cell line overexpressing the T-antigen for enhanced CMV promoter 
expression; kind gift of Dr. Steven Marx) were grown in DMEM + 10% FBS.  AC-16 cells 
(human ventricular cell line (Davidson et al, 2005); kind gift of Dr. Mercy Davidson) were 
grown in DMEM-F12 + 15% FBS.  CHO-1F8 cells (CHO cell line overexpressing the PAF 
receptor) were grown in F12 + 10% FBS containing 300 µg/ml G418.  COS-7 cells were grown 
in DMEM + 10% FBS.   None of the alternate cell lines resulted in improved hTASK-1 
solubility. 
 Alternate sample preparations were also attempted.  In some experiments, cultured cells 
were pretreated for 30 min with 1 mM dithiothreitol followed by 5 mM N-ethylmaleimide 
(NEM).  Homogenization buffer, homogenization buffer + 1% Triton-X100 (membrane 
resuspension buffer), and Laemmli sample buffer were all supplemented with 100 mM NEM 
during the subsequent sample preparation steps.  In other experiments, urea was added to 





disrupted directly in homogenization buffer containing 1% Triton-X100 without membrane 
fractionation, or else disrupted in an alternative lysis buffer containing 50 mM Tris HCl pH 7.4, 
150 mM NaCl, 1 mM DTT, 1 mM EDTA, 1 µM leupeptin, 1µM pepstatin A, 0.5 mM PMSF, 0.1 
µM aprotinin, 1 µg/ml benzamidine, 1 mM activated NaVO4, 5 mM NaF, 1% triton-X100, 1% 
DOC-Na, 0.5% NP40, and 0.1% SDS.  Alternately, after transfection and treatment, cells were 
resuspended in cold enzyme-free cell dissociation buffer (Gibco), centrifuged at 1000g, and the 
resulting cell pellet was resuspended and lysed directly in Laemmli sample buffer.  As an 
alternative to boiling samples before SDS-PAGE, some preparations were mixed with Laemmli 
sample buffer and incubated at 60°C, 40°C, or room temperature.  None of the alternate sample 
preparation techniques resulted in improved hTASK-1 solubility. 
 
Treatment of canine atrium with C-PAF 
 Canine right atrium was taken from normal control dogs and minced.  50-200 mg of 
tissue was incubated in 2 ml modified Tyrode containing (in mM): NaCl 140, KCl 5.4, CaCl2 1, 
MgCl2 1, HEPES 5, glucose 10, NaF 1, adjusted to pH 7.4 and with an osmolarity ~298 mOsm.  
Reactions were bubbled with O2, and 0, 0.2, or 2.0 µM C-PAF was added for 15 min incubation.  
In some experiments, the isoform-nonspecific PKC inhibitor Bisindomalaamide-1 (GF 109203X, 
Sigma) was added to the incubations at a final concentration of 5 µM, 5 min before the addition 
of C-PAF.  Tissue was removed from the incubation bath and frozen.  Samples were processed 
and immunoblotted as described below, and the change in phosphorylation at T383 compared to 






Canine peri-operative AF model 
 This study was performed under a protocol approved by the Institute of Animal Care and 
Use Committee of Columbia University, using a modification of the method reported by Ishii et 
al (2005).  Surgeries were performed by the labs of Dr. Michael Rosen and Dr. Michael 
Argenziano.  Animals were anesthetized with thiopental sodium (17 mg/kg IV) and ventilated 
with isoflurane (1.5-2%) and O2 (2 l/min).  A thoracotomy was performed on adult male mongrel 
canines weighing 25-35 kg.    A 5 cm right atriotomy was performed and tissue was collected 
into cold saline for processing and analysis.  Electrical leads were placed on the high and mid 
atrium for recording, and low atrium for pacing.  The chest was closed and the animal allowed to 
recover with appropriate pain management.  Three days later, the animals were reanesthetized, 
the chest reopened, and the heart subjected to 30 s bursts of pacing, at decreasing cycle lengths 
starting at 30ms above the ERP, until atrial fibrillation was induced or until reaching 50 ms.  If 
AF was not induced, the heart was allowed to rest 30 min before attempting again.  If AF was 
induced, it was allowed to continue until it spontaneously converted to normal sinus rhythm, or 
was electrically cardioverted after 30 min.  The experiment continued for 5 h after the first 
induction attempt, or until there were 3 consecutive unsuccessful induction cycles.  A 
cardiectomy was performed, and the right atrium was dissected and collected into cold saline for 
immediate myocyte isolation, or frozen for later processing and analysis.  35 surgeries were 
performed in total, and AF was successfully induced in 24 animals (68.6%).   However, due to 







Canine rapid-pacing AF model 
 This study was performed under a protocol approved by the Institutional Animal Care and 
Use Committee of Columbia University.  Surgeries were performed by the lab of Dr. Michael 
Rosen.  Pacemakers were implanted in female adult mongrel dogs weighing 24-26 kg, following 
the procedure previously described by Yagi et al. (2002).  Animals were anesthetized with 
thiopental sodium (17 mg/kg IV) and ventilated with isoflurane (1.5-2%) and O2 (2 l/min).  
Active fixation leads were implanted in the right atrial (RA) appendage and right ventricular free 
wall and connected to an Itrel pulse generator and Thera 8962 pacemaker, respectively 
(Medtronics). Complete atrioventricular block was generated by injection of 40% formaldehyde 
(0.1-0.3 ml) into the His bundle.  Immediately after surgery the ventricular pacemaker was 
programmed at a rate of 60 bpm to ensure a physiological ventricular rate during recovery.  After 
2 weeks of recovery, atrial pacing was instituted at a rate of 600 to 900 bpm and maintained for 
4-6 weeks.  During this period the dogs were studied weekly with measurements of the ECG.  
Following this protocol, the majority of the paced animals developed chronic AF (defined as >5 
days of AF in the absence of continued pacing) and were in this rhythm at the time of euthanasia.  
Sham animals were similarly operated and instrumented, but were implanted with 
nonfunctioning right atrial leads.  The ventricles of these sham animals were paced at 60 bpm for 
50 days.  At the time of euthanasia, animals were anesthetized with pentobarbital (30 mg/kg), 
and hearts were removed.  Tissue was collected from the right atrial free wall for immediate 







 Samples and patient data were collected and used according to a protocol approved by the 
Institutional Review Board of Columbia University.  Tissue samples and patient data were 
collected through a collaboration with the Columbia University Medical Center Department of 
Surgery, by the lab of Dr. Michael Argenziano.  Samples of left atrial free wall were obtained as 
surgical specimens from patients undergoing cardiac surgery.  Most patients were undergoing 
mitral valve repair or replacement, and patients in AF were often also undergoing the MAZE 
procedure.  Tissue was collected into physiological solution, and then immediately processed for 
myocyte isolation or else frozen at -80°C for later processing and analysis. 
 
Myeloperoxidase assay 
 Atrial tissue was frozen after collection, and was prepared and analyzed using a 
modification of the method of Bradley et al (1982).  Tissue was thawed, minced and 
homogenized in 50 mM KPO4 buffer (pH 6.0) containing 0.5% hexadecyltrimethylammonium 
bromide.  The homogenate was sonicated 10 s, freeze-thawed in a dry ice acetone bath, sonicated 
an additional 10 s, and centrifuged at 40000g.  Samples were read in duplicate in a 96-well plate 
format, combining 100 µl supernatant with 100 µL KPO4 (pH 6.0) containing 0.67 mg/ml o-
dianisidine dihydrochloride and 0.002% H2O2.  The increase in absorbance at 450 nm was 
measured 10 times in 10 s increments using an EL312 plate reader (Biotek).  The slope of this 
change in absorbance was compared to that of a standard curve of purified human leukocyte 






 In some experiments, isolated canine neutrophils were thawed and myeloperoxidase 
enzyme was released from the cells by sonication and freeze-thaw treatments, as described 
above. The myeloperoxidase activity of extracts from 104-106 PMNL were measured against a 
standard curve of purified MPO enzyme as described above.  It has previously been reported that 
in this assay, MPO activity is linear from 105-106 cells, and based on that study, we expected 0.6 




 20 ml intravenous blood was collected from a normal dog into 5 ml anticoagulant 
containing 0.14 M citric acid, 0.2 M trisodium citrate, and 0.22 M dextrose.  Blood was mixed 
with 7.5 ml 2% dextran-500 in 0.9% NaCl, and red blood cells were allowed to sediment for 2 h.   
The upper leukocyte-rich layer was aspirated and subjected to centrifugation at 200g for 10 min.  
The pellet was resuspended in erythrocyte lysis buffer composed of 20 mM Tris HCl pH 7.4 and 
140 mM NH4Cl, and incubated at 37°C for 7 min.  After centrifugation at 100g for 15 min, the 
PMNL-enriched cell pellet was resuspended in PBS to a final concentration of 108 cells/ml, and 
stored at -80°C. 
 
Isolation of atrial myocytes 
 Atrial tissue was first minced in physiological solution (composition in mM: NaCl 140, 





calcium-free solution (composition in mM: NaCl 140, KCl 5.4, HEPES 5, MgCl2 0.5, KH2PO4 
1.2, glucose 5.5, taurine 50, pH 6.9).  Next the pieces were immersed in an enzyme solution and 
bubbled with O2 at 37º C.  The enzyme solution was made by adding collagenase (59.4 U/ml; 
Worthington CLS2, 198 U/mg) and protease (0.52 U/ml; Sigma type XIV, 5.2 U/mg) to the 
calcium-free solution.  45-60 min after the initial exposure of the tissue to the enzymes and every 
10-15 min thereafter, the supernatant was checked for the appearance of myocytes.  If myocytes 
were present, the supernatant was centrifuged and the pellet was resuspended in calcium-free 
physiological solution and then slowly adapted to a physiological Ca2+ concentration (1 mM).  
Only the rod shaped and striated myocytes were used for electrophysiological studies. 
 
Measurement of native TASK-1 currents in myocytes 
 Cells were placed into a perfusion chamber mounted on the stage of an inverted 
microscope, and only rod shaped and striated atrial myocytes were studied.  The cells were 
superfused at room temperature with a modified Tyrode’s solution containing high K+ to 
linearize the TASK-1 current-voltage relation, and channel blockers (to minimize other 
endogenous currents).  The solution was composed of (in mM): NaCl 100, KCl 50, CaCl2 1, 
MgCl2 1, HEPES 5, glucose 10, CsCl 5, TEA 1, nifedipine 5 µM, adjusted to pH 7.4 and with an 
osmolarity ~298 mOsm.  Current was measured in the absence and presence of the TASK-1 
blocker methanandamide (10 µM), and TASK-1 current was defined as the methanandamide-
sensitive difference current (Fig. 14).  Currents were recorded in whole cell configuration using a 
ramp protocol from –50 mV to + 30 mV over 6 s.  Borosilicate glass pipettes with a tip 





aspartic acid 130, KOH 146, NaCl 10, CaCl2 2, EGTA 5, HEPES 10, MgATP 2, adjusted to pH 
7.2 and with an osmolarity ~ 295 mOsm.  In some recordings, the tip of the pipette was filled 
with the phosphatase PP2A (1 U/ml) and the back of the pipette was filled with regular pipette 
solution.  The recordings started 10-12 min after rupture to allow the PP2A time to dialyze into 
the cell. 
 The voltage clamp protocols were generated using Clampex 8.0 software applied by 
means of an Axopatch 200-B and a Digidata 1200 interface (Axon Instruments).  Current signals 
were filtered at 2 KHz and acquired at 500 Hz.  All recordings were corrected for the junctional 
potential (-9.8 mV). 
 
Total and pT383 TASK-1 immunoblotting in AF models 
 Frozen tissue from canine right atrium or human left atrium was thawed and 
homogenized using a polytron in a detergent-free homogenization buffer (50 mM Tris-HCl pH 
7.4, 150 mM NaCl, 1 mM EGTA, 250 mM sucrose, 0.1 mM PMSF, 1 ng/ml apoprotinin, 1 
ng/ml leupeptin, 0.1 µM pepstatin, 1 µg/ml benzamidine, 1 mM activated sodium orthovanadate, 
5 mM NaF).  Debris was removed by centrifugation at 3000g, and then the supernanant was 
fractionated into crude membrane and cytosol fractions by ultracentrifugation at 160000g.  
Membrane pellets were resuspended in the homogenization buffer containing 1% Triton and 
sonicated.  Total protein concentration was determined by a modification to the method of 
Lowry (Peterson GL, 1977).  Twenty µg of total protein from each sample were loaded and run 
onto duplicate 8 or 10% Polyacrylamide Tris-Glycine gels, and transferred to nitrocellulose 





antibody that recognizes total TASK-1 (Biomol; 1.4 µg/ml) or the pT383 PSSA described above 
(10mg/ml), followed by incubation with HRP-conjugated anti-rabbit antibody and 
chemiluminescent substrate (Pierce West Pico) and exposure to x-ray film.  Films were scanned 
and band pixilation was calculated using ImageJ software (NIH).  All total TASK-1 and pT383 
blots were run and exposed in parallel.  In order to approximate the fraction of TASK-1 channels 
that were phosphorylated, average pT383 signal was expressed as a ratio of average TASK-1 
signal.  Western blots were repeated 2-3 times, as sample volumes allowed. 
 
Statistical analysis 
 All values are reported as average ± SEM.  Data was analyzed in Graph Pad (InStat), by 
Fisher's Exact test, Student's t-test or ANOVA followed by post-hoc analysis according to 
Dunnet or Tukey, as appropriate.  In "Treatment of Canine Atrium with C-PAF," data was 
analyzed by a repeated measures ANOVA, and total and pT383 TASK-1 immunoblotting in the 





CHAPTER 3.  IDENTIFICATION OF A PAF RECEPTOR AND PKCε – DEPENDENT TASK-1 
PHOSPHORYLATION SITE 
 
Previous studies from our laboratory showed that either C-PAF or PMA could activate 
phosphorylation of murine TASK-1 at T381. This phosphorylation inhibits TASK-1 current 
when the channel is expressed in a heterologous mammalian cell system (Besana et al, 2004).  
However, the human and canine sequences differ from the mouse, and rather than a single 
consensus PKC site, they instead contain at least two putative PKC phosphorylation targets in 
this region of the C-terminus: S358 and T383.   
 
T383 of TASK-1 C-terminus is phosphorylated by PKCε in vitro 
In order to take a purely unbiased approach to identifying native phosphorylation sites in 
this channel, attempts were made to immunoprecipitate TASK-1 from canine atrial tissue, with 
the goal of then identifying phosphorylation modifications to the purified protein by LC-MS/MS.  
Unfortunately, much of the TASK-1 protein aggregated during the immunoprecipitation 
procedures, and only a small amount of enriched TASK-1 was eluted from the antibody resin.  
This TASK-1 band showed immunoreactivity for both phosphoserine and phosphothreonine (Fig 
1).  However, there was insufficient material to obtain a convincing LC-MS/MS result using the 
excised band.   
After these experiments in native tissue failed to identify phosphorylation sites, attempts 





overexpressed in CHO cells.  The FLAG epitope-was inserted into the N-terminus of hTASK-1, 
and the tagged human TASK-1 protein was transfected into CHO cells.  Cells were treated with 
C-PAF, and tagged hTASK-1 was immunoprecipitated using an antibody to the FLAG epitope, 
again with the intent of using LC-MS/MS to detect phosphorylation sites.  However, the channel 
repeatedly came out of solution during immunoprecipitation, and aggregated with the antibody 
resin (Fig 2).  This aggregation occurred whether protein was eluted with excess FLAG epitope 
or with acid, and also occurred in different binding buffers.  
Because experiments in the full-length channel were technically problematic, efforts were 
instead made to purify just the C-terminal portion of the channel, and to perform an in vitro 
phosphorylation with recombinant PKCε, which was previously shown to be required for C-
PAF-dependent TASK-1 inhibition in mouse ventricular myocytes (Besana et al, 2004).  
Constructs were made of glutathione-S-transferase (GST) fused to various portions of the 
hTASK-1 C-terminus (Fig 3), so as to facilitate the purification of the fusion protein based on 
GST's affinity for its substrate glutathione.  These purified constructs could then be incubated 
with PKCε, and reisolated for analysis of any phosphorylation using LC-MS/MS.   
The 43-kDa fusion protein consisting of the full-length C-terminus (residues 244-394) 
fused to GST was insoluble, and lysozyme treatment revealed that it localized to inclusion bodies 
(Fig 4 A).  Alterations to bacterial growth and induction conditions did not improve solubility, 
and the fusion protein was unable to be purified.  Attempts to refold the denatured lysozyme-
liberated GST-fusion protein also failed.  The GST-fusion protein of the C-terminal residues 





In an effort to prevent aggregation and to focus on the region of the C-terminus 
containing the putative phosphorylation sites, a GST-fusion protein of just the distal 45 amino 
acids of TASK-1 (residues 350-394), was made.  This construct was soluble and was expressed 
in E. coli and purified on a GST affinity column (Fig 4 B).  This 31-kDa distal C-terminal fusion 
protein was also made with mutations in the putative phosphorylation sites, S358A or T383A.  
These distal C-terminal fusion proteins were incubated with recombinant PKCε in the presence 
of [γ−32P]ATP and the PKC activator PMA, and the reaction products were resolved by SDS-
PAGE and transferred to nitrocellulose.  When the nitrocellulose was exposed to x-ray film, 
bands appeared where PKCε had successfully incorporated 32P into the protein.  The T383A 
mutant failed to incorporate radioactive phosphate whereas the S358 mutant was identical to 
wild-type, indicating that T383 but not S358 is necessary for phosphorylation by PKCε (Fig 5 
A).   
In order to isolate individual phospho-peptides, the phosphorylated wild-type, T383A, 
and S358A TASK-1 C-terminus GST fusion proteins were excised from the nitrocellulose 
membrane, trypsin-digested, and resolved by HPLC, and radioactivity was measured from eluted 
fractions.  This peptide mapping revealed a phosphorylated peptide that eluted as a differentially-
digested doublet, which was present in wild-type and S358A C-terminal fusion protein digests, 
but not in T383A (Fig 5 B).  Trypsin cleaves peptides C-terminal to arginine and lysine residues, 
but may miss cleavage sites when two sites are in close proximity, or when there is a negative 
charge located close to a predicted cleavage site (Siepen et al, 2007).  The region of the hTASK-
1 C-terminus in which T383 is located has two potential cleavage sites in close proximity, R385 





S369-R385 and S369-K389 peptides.  Therefore, this doublet with high levels of 32P 
incorporation may correspond to the two differentially digested peptides containing T383. 
In separate experiments, in vitro phosphorylation of the wild-type fusion protein by 
recombinant PKCε was repeated, without radioactive tracer. Direct PKCε phosphorylation of the 
wild-type fusion protein at T383 was confirmed by LC-MS/MS (Fig 5 C).  Phosphorylated 
threonine was detected by mass identification of dehydroamino-2-butyric acid in the peptide 
sequence, corresponding to phospho-threonine that has lost the phosphate group plus water.  
Therefore, T383 in the hTASK-1 C-terminus is a direct PKCε phosphorylation site in vitro. 
 
T383 is necessary for C-PAF-dependent inhibition of TASK-1 
Since T383 of the hTASK-1 distal C-terminus is directly phosphorylated by PKCε in 
vitro, it was hypothesized that T383 could play a role in the C-PAF-dependent inhibition of 
hTASK-1, which has been shown to require PKCε (Besana et al, 2004).  Therefore, currents 
were measured in voltage-clamp mode in CHO cells expressing the full length wild type, T383A, 
or S358A hTASK-1.  Current was measured before and after the addition of 185 nM C-PAF to 
the perfusate, and a C-PAF-sensitive difference current was calculated.  The total current 
densities were similar in cells expressing each of the constructs (Fig 6); however their response 
to C-PAF differed (Fig 7 A).  In cells expressing wild type (n=7) and S358A (n=12) hTASK-1, 
C-PAF caused a significant inhibition in current (12.6 ± 2% and 12.5 ± 3% average decrease in 
currents at +30 mV, respectively).  In contrast, the C-PAF-dependent difference current was 





n=14 cells; p<0.001 vs. wild type) (Fig 7 C, left bars).  Therefore, T383 is necessary for C-PAF-
dependent channel inhibition in vitro. 
In order to determine whether this C-PAF-dependent channel inhibition required PKCε, a 
PKCε inhibitory peptide (Besana et al, 2004; Johnson et al, 1996) was added to the patch pipette.  
Addition of the inhibitory peptide prevented the C-PAF-dependent channel inhibition of wild 
type hTASK-1 (1.0 ± 3.2 % average decrease in current at +30 mV; n=9; p<0.005).  Addition of 
a scrambled control peptide had no effect on the amount of C-PAF-sensitive current (10.5 ± 0.7 
% average decrease in current at +30 mV; n=8) (Fig 8).  Addition of the inhibitory peptide also 
prevented the C-PAF-dependent channel inhibition of S358A hTASK-1 (1.9 ± 2.6% average 
decrease in current at +30 mV; n=9), but had no effect on the already C-PAF-resistant T383A 
mutant (2.0 ± 1.7% average decrease in current at +30 mV).  Therefore, just like previously 
shown in the mouse channel (Besana et al, 2004), the C-PAF dependent inhibition of hTASK-1 
requires PKCε. 
Interestingly, T383 was not necessary for PMA-dependent inhibition of hTASK-1 in 
CHO cells.  When current was measured before and after the addition of 100 nM of the 
nonspecific PKC activator PMA, there was a PMA-dependent current decrease in wild type 
TASK-1 (18.5 ± 4.6 % average decrease at +30mV; n=11) and in T383A TASK-1 (20.4 ± 3.5 % 
decrease at +30 mV; n=13).  The S358A mutant, however, showed less PMA-dependent 
inhibition (3.85 ± 3.25 % decrease at 30 mV; n=10; p=0.05) (Fig 7 B and 7 C, right panel), 
indicating that there is another PKC-dependent phosphorylation event that requires S358 and 





inhibited TASK-1 and required a single site (T381), in the human channel two putative PKC 
target sites are involved in TASK-1 inhibition by two different stimuli. 
 
Validation of a phospho-T383 specific antibody 
After identifying T383 as a PKCε phosphorylation target in the human/canine TASK-1 channel, 
it was desirable to have a phosphorylation site-specific antibody (PSSA) made against 
phosphorylated T383 (pT383) in order to biochemically track phosphorylation at this site.  The 
pT383 PSSA recognized PKCε -phosphorylated hTASK-1 C-terminal GST fusion protein, but 
did not recognize protein not phosphorylated by PKCε, phosphorylation site-null protein 
(T383A), or phosphorylated protein that was subsequently dephosphorylated by treatment with 
acid phosphatase (Fig 9).  Total GST signal was similar for all samples, and demonstrated a band 
shift when dephosphorylated. 
 
C-PAF Signaling Results in an increase in T383 phosphorylation in a heterologous 
expression system 
All previous biochemical work identifying T383 as a direct phosphorylation site was 
performed using a GST-fusion construct of the distal 45 residues of hTASK-1.  It was important 
to confirm whether this site was also phosphorylated in the full-length channel, as detected by 
our novel PSSA.  The wild-type hTASK-1 channel was overexpressed in CHO and TSA201 
HEK cells which were then treated with or without C-PAF, and cell extracts were resolved by 





of hTASK-1 or T383A hTASK-1 in pDC-IE resulted in a robust TASK-1 signal that runs as a 
high molecular weight aggregate at the top of the SDS-polyacrylamide gel.  Several attempts to 
disaggregate this complex, by expression in different cell lines, different methods of cell lysis 
and sample preparation, and different gel running conditions, failed.  This high-molecular weight 
TASK-1 complex was also recognized by the pT383 PSSA.  Phospho-T383 signal increased in 
extracts from wild type hTASK-1-transfected cells after 20 minutes of treatment with 1 µM C-
PAF (Fig 10).  Phospho-T383 signal was absent in extracts from nontransfected CHO cells, and 
in extracts from cells transfected with phosphorylation site-null T383A hTASK-1.  Given that 
the pT383 PSSA band co-localizes with the total TASK-1 band, which recognizes a distinct 
epitope, it is likely that this truly is TASK-1, despite the anomalous apparent molecular weight 
on the gel.  This indicates that signaling downstream of C-PAF treatment results in 
phosphorylation of the full-length hTASK-1 channel at T383.   
 
C-PAF treatment results in increased T383 phosphorylation in native canine atrial tissue 
After demonstrating a C-PAF-dependent increase in T383 phosphorylation in TASK-1 
heterologously overexpressed in cultured cells, it remained to be determined whether this site 
was targeted in native heart tissue.  Minced myocardium from the right atrium of a normal 
control dog was exposed to various concentrations of C-PAF, and the amount of total and pT383 
signal was quantified by immunoblot (Fig 11 B).  After 15 minutes of treatment, there was a 
significant increase in the ratio of pT383 to total TASK-1 (0.35 ± 0.05 at 0 µM, 0.66 ± 0.15 at 





panel).  Therefore, TASK-1 is phosphorylated at T383 downstream of C-PAF signaling in native 
atrial myocardium.  
In patch clamp experiments measuring the C-PAF-dependent inhibition of TASK-1 
currents in CHO cells, inhibition of TASK-1 downstream of C-PAF required PKCε (see Fig 8).  
In order to determine whether the C-PAF-dependent increase in T383 phosphorylation in canine 
atrium likewise required PKC, the isoform-nonspecific PKC inhibitor BIM-1 (5 µM) was added 
to the incubations 5 min before the addition of C-PAF.  Inhibition of PKC attenuated the C-PAF-
dependent increase in the ratio of pT383 to total TASK-1 signal (0.36 ± 0.16 at 0 µM, 0.17 ± 
0.07 at 0.2 µM, and 0.33 ± 0.15 at 2 µM, for a 1.0 ± 0.4 -fold change; n=3; N.S.) (Fig 11 A, right 
panel).  Therefore, the C-PAF-dependent phosphorylation of TASK-1 in atrial myocardium at 
T383 requires PKC. 
 
This chapter has described the identification of a phosphorylation site in hTASK-1, T383.  
This site is phosphorylated directly by PKCε in vitro, and is necessary for the C-PAF-dependent 
inhibition of TASK-1 currents.  Furthermore, the development of a novel PSSA that recognizes 
phosphorylation at T383 has allowed the demonstration that this site is phosphorylated 
downstream of C-PAF signaling in cultured mammalian cells and in native canine atrial 
myocardium.  The identification of T383 as an inhibitory phosphorylation site targeted 
downstream of C-PAF signaling suggests that phosphorylation at this site could contribute to the 
C-PAF-dependent TASK-1 inhibition and repolarization abnormalities previously seen in 





Figure 1: Immunoprecipitation of TASK-1 from canine right atrium. 
Canine right atrial free wall was homogenized ("Total Lysate") and TASK-1 was 
immunoprecipitated using an antibody to the 252EDEKRDAEHRALLTRNGQ269 epitope of 
hTASK-1 ("Eluted TASK-1").  Reactions were resolved by SDS-PAGE and blotted to 
nitrocellulose by standard protocols.  TASK-1 runs as a 52-kDa band, detected by the TASK-1 
antibody (left panel), or an antibody to phospho-serine (center panel) or phospho-threonine (right 
panel).  The TASK-1 band shows affinity for both pSer and pThr antibodies, suggesting that the 
native channel is phosphorylated at both serine and threonine residues.  Subsequent LC-MS/MS 












Figure 2: Immunoprecipitation of FLAG-hTASK-1 from CHO cells 
FLAG-tagged hTASK-1 was expressed in CHO cells ("preload") and immunoprecipitated using 
an antibody to the FLAG epitope by elution with excess FLAG peptide ("FLAG-eluted") or by 
addition of an acidic elution buffer ("HCl-eluted"), and immunoblotted for TASK-1 signal.  Four 
binding and washing buffers were used: RIPA (left panel), RIPA containing twice the 
concentration of NaCl (second panel), RIPA supplemented with 10% glycerol (third panel), or 
RIPA containing twice the concentration of NaCl and 10% glycerol (right panel).  In each 
attempt, TASK-1 signal is absent from eluates of the immunoprecipitation, but immunoreactivity 












Figure 3: Construction of  hTASK-1 C-terminus GST fusion proteins 
Various portions of the hTASK-1 C-terminus were fused to glutathione-S-transferase.  Fusion 
proteins were made containing the entire hTASK-1 C-terminus (L244-V394), a shorter portion 
of the C-terminus (H260-V394), or the distal 45 residues (G350-V394).  All fusion proteins 












Figure 4: GST-pulldown of hTASK-1 C-terminal-GST fusion constructs. 
The full-length (L244-V394)  or distal 45 residues (G350-V394) of hTASK-1 C-terminus were 
fused to GST, expressed in E. coli, and purified from the soluble extract using immobilized 
glutathione.  4% of the volume at each step was resolved by SDS-PAGE, blotted to 
nitrocellulose, and protein was visualized using an antibody against GST.  A.  The full-length C-
terminus fusion protein ran as a 43-kDa band, and endogenous bacterial GST ran as a 23-kDa 
band.  Full-length hTASK-1 C-terminus GST fusion protein was insoluble, and localized to 
inclusion bodies ("Lysozyme pellet").  B.  The distal 45 residue C-terminus GST fusion protein 
ran as a 31-kDa band.  The fusion protein was soluble, and purified protein was successfully 






























Figure 5: T383 of hTASK-1 C-terminus GST fusion protein is phosphorylated by PKCε 
Purified GST fusion constructs of the distal 45 residues of the C-terminus of human TASK-1 
were phosphorylated by PKCε in the presence of [γ−32P]ATP.  A.  Reactions were resolved by 
SDS-PAGE, blotted to nitrocellulose, and analyzed by exposure to X-ray film.  The presence of 
bands indicates the incorporation of 32P.  T383 was required for successful phosphorylation by 
PKCε.  B. Proteins were excised from the membrane, and digested by trypsin.  Peptides were 
fractionated by RP-HPLC and eluted peptides were collected in 30 s increments for Cherenkov 
counting.  Peptide mapping revealed that a differentially digested phosphorylated peptide eluting 
at 7.5 and 9 min was present in reactions with wild type or S358A TASK-1 C-terminus, but not 
T383A.  C.  In separate in vitro kinase reactions performed in the absence of [γ−32P]ATP, LC-
MS/MS fragmentation revealed direct phosphorylation of the wild-type hTASK-1 C-terminus 
GST fusion protein at T383. The mass spectrum of a phosphorylated peptide is shown, with eight 
characteristic fragment peaks (y1-y11) that allowed identification of the peptide sequence, 
indicated above.  The difference in masses of adjacent peaks corresponds to the mass of the 
amino acids in sequence.  T* indicates an identified dehydroamino-2-butyric acid residue 


































Figure 6: Whole cell currents of CHO cells transfected with WT, S358A, or T383A hTASK-
1 demonstrate similar I/V relations and current densities.   
Wild-type, S358A, or T383A hTASK-1 were expressed in CHO cells, and current was recorded 
using a voltage clamp protocol (ramp from –110 to +30 mV in 6 s) in whole cell configuration.  
A. Representative example traces of WT (left panel), S358A (center panel) and T383A (right 
panel) I/V relations.  B. Average current density at +30 mV for cells expressing WT, S358A, and 
T383 hTASK-1.  No significant differences in total current were found between mutants.  Error 





















































































Figure 7: T383 is necessary for C-PAF dependent, but not PMA-dependent, inhibition of 
hTASK-1. 
Full-length wild-type, S358A, or T383A hTASK-1 were expressed in CHO cells, and current 
was measured by patch-clamp recording in whole cell configuration before and after the addition 
of 185 nM C-PAF or 100 nM PMA.      A.  Averaged I/V traces of calculated C-PAF-sensitive 
difference currents of WT, S358A, and T383A hTASK-1.  Cells expressing WT or S358A 
hTASK-1 displayed measurable C-PAF-sensitive current, whereas cells expressing T383A 
displayed no C-PAF-dependent inhibition.  B.  Averaged I/V traces of calculated PMA-sensitive 
difference currents of WT, S358A, and T383A.  Cells expressing WT and T383A hTASK-1 
displayed measurable PMA-sensitive current, whereas cells expressing S358A displayed less 
PMA-dependent inhibition.  C.  Average percent inhibition of hTASK-1 current densities in WT, 
S358A, and T383A constructs by C-PAF (left) and PMA (right), measured at +30 mV.  T383 
hTASK-1 was resistant to C-PAF-dependent inhibition (p=0.001 vs. WT) and S358A hTASK-1 
was resistant to PMA-dependent inhibition (p=0.05 vs. WT).  N=7-14 cells; error bars represent 





























Figure 8: C-PAF dependent inhibition of TASK-1 requires PKCε. 
Wild Type, S358A, or T383A hTASK-1 were expressed in CHO cells and current was measured 
by patch-clamp recording in whole cell configuration before and after the addition of 185nM C-
PAF.  A PKCε inhibitor peptide or a scrambled control peptide was added to the patch pipette 
before recording.  Whereas the scrambled control peptide had no effect on C-PAF-sensitive 
TASK-1 current, inhibition of PKCε resulted in a reduction of C-PAF-dependent inhibition in all 
previously responsive constructs (p<0.05).  N=7-10 cells; error bars represent SEM.  Data 



































































Figure 9: A pT383 PSSA recognizes PKCε-phosphorylated, but not nonphosphorylated or 
dephosphorylated hTASK-1 C-terminus fused to GST. 
Western blot analysis of in vitro kinase reactions of WT or T383A hTASK-1 C-terminus fused to 
GST that were phosphorylated (lanes 1 and 4), or not phosphorylated (lane 2), by PKCε (left 
panel).  Some reactions were subsequently dephosphorylated by acid phosphatase (lane 5, right 
panel).  Proteins were resolved by SDS-PAGE and transferred to nitrocellulose.  Phosphorylated 
T383 was detected by immunoreactivity with a PSSA (top), and total protein loading was 
confirmed by immunoreactivity with an anti-GST antibody (bottom).  The pT383 PSSA is 
specific for the phosphorylated C-terminus (lanes 1 and 4), and does not recognize protein that 
was not exposed to PKCε (lane 2), protein where the T383 phosphorylation site was mutated 






























Figure 10: C-PAF treatment of cells transfected with hTASK-1 results in increased pT383 
signal 
Western blot analysis of full length wild type or T383A hTASK-1 transfected into CHO cells (A) 
or TSA-201 cells (B), untreated or treated with 1 µM C-PAF.  Samples were immunoblotted 
using an antibody to total TASK-1 (left panels) or the pT383 PSSA (right panels).   TASK-1 ran 
as a >250-kDa aggregate.  C-PAF resulted in an increase in pT383 signal at this high molecular 

























Figure 11: C-PAF treatment of normal dog right atrial tissue results in a PKC-dependent 
increase in pT383 signal 
Normal canine right atrium was incubated with 0, 0.2, or 2 µM C-PAF for 15 min, with or 
without a 5 min pretreatment with the PKC inhibitor BIM-1 (5 µM).  Crude membrane fractions 
of the homogenized tissue were analyzed by western blot using antibodies against total TASK-1 
and pT383 TASK-1.  A.  C-PAF treatment resulted in a significant increase in pT383 signal 
relative to total TASK-1 (p<0.05 0.2 vs. 0 µM; p<0.01 2 vs. 0 µM;  n=8).  Inhibition of PKC 
attenuated this C-PAF-dependent increase in phosphorylation (n=3).  B.  Representative western 


























CHAPTER 4.  THE ASSOCIATION BETWEEN INFLAMMATION, TASK-1 INHIBITION, T383 
PHOSPHORYLATION, AND ATRIAL FIBRILLATION 
 
Since it has been demonstrated that inhibition of TASK-1 causes repolarization abnormalities in 
isolated myocytes, and since the previous chapter demonstrated that TASK-1 is inhibited 
downstream of C-PAF inflammatory signaling, a relationship between TASK-1 inhibition, T383 
phosphorylation, inflammation, and arrhythmias was suggested. 
 
Chapter 4.1: Peri-operative AF 
The relationship between TASK-1 inhibition, T383 phosphorylation, inflammation, and 
arrhythmias was initially studied in a model of atrial fibrillation known as canine peri-operative 
atrial fibrillation (POAF).  In this model, designed to mimic the acute onset of peri-operative AF 
after cardiothoracic surgery in human patients, an atriotomy is performed in order to create an 
inflammatory and structural insult, and recording and pacing electrodes are implanted on the 
right atrium (Fig 12).  Three days later, the dog is subjected to brief bursts of tachycardic pacing, 
which in this vulnerable substrate resulted in AF induction in 69% (24/35) of animals.   
 
Neutrophil myeloperoxidase activity is significantly increased after induction of peri-
operative AF 
This model of acute-onset AF has previously been shown to have a robust inflammatory 





the heterogeneity of conductance (Ishii et al, 2005).  To determine if a similar change was 
occurring in these animals, neutrophil myeloperoxidase (MPO) activity in cardiac tissue excised 
from POAF dogs was measured and compared to control tissue taken at the time of atriotomy 
("pre-operative").  Tissue from dogs with POAF contained 36.8 ± 4.8 units/gram (n=17), versus 
1.0 ± 0.2 units/gram in control pre-operative tissue (n=17; p<0.001) (Fig 13).  This increase in 
myeloperoxidase demonstrates a marked influx of neutrophils into the cardiac tissue.  In a 
separate experiment, neutrophils were purified from the blood of a control dog, and 
myeloperoxidase levels were measured, demonstrating that 106 cells contained 0.577 units MPO.   
Thus, it can be extrapolated that there were 1.7 ± 0.4 x106 neutrophils per gram control tissue, 
versus 63.8 ± 8.4 x 106 neutrophils per gram AF tissue.  
 
Induction of POAF results in a phosphorylation-dependent loss of TASK-1 current 
Since neutrophil-derived PAF is known to inhibit TASK-1, and POAF was shown to be 
associated with a significant increase in neutrophil infiltration into atrial myocardium, the 
TASK-1 current density in cells from dogs before or after POAF induction was investigated.  
Currents were measured by patch-clamp recording in voltage-clamp mode in isolated atrial 
myocytes in the presence of elevated external K+ (to increase the inward component of the 
TASK-1 current and to linearize the TASK-1 I/V), and in the presence of TEA, CsCl, and 
nifedipine (to block other endogenous currents).  Currents were measured before and after the 
addition of methanandamide to the perfusate, and TASK-1 was defined as the methanandamide-
sensitive difference current (Fig 14).  TASK-1 current was measured in atrial myocytes isolated 





present in cells from control atrial tissue (0.47 ± 0.10 pA/pF at +30 mV; n=52 cells from 21 
dogs), but was absent in cells from dogs with POAF (-0.02 ± 0.08 pA/pF at +30 mV; n=19 cells 
from 7 dogs; p<0.0001) (Fig 15, filled circles).  In separate cells, when the serine/threonine 
phosphatase PP2A was added to the patch pipette, TASK-1 current levels were similar to control 
(0.27 ± 0.05 pA/pF at +30 mV; n=16 cells from 7 dogs), indicating that TASK-1 is inhibited in a 
phosphorylation-dependent manner in atrial myocytes from dogs with POAF (Fig 15, open 
circles).  Addition of PP2A to the patch pipette had no effect on control cells (0.36 ± 0.05 pA/pF; 
n=50 cells from 20 dogs), indicating that there was no measureable basal phosphorylation-
dependent inhibition in control atrial cells. 
 
Induction of POAF results in a marked increase in T383 phosphorylation 
Since T383 is phosphorylated downstream of inflammatory C-PAF signaling, it is possible that 
phosphorylation at this site is responsible for the phosphorylation-dependent loss of TASK-1 
current seen in POAF.  Western blot analysis was used to measure the change in total and pT383 
TASK-1 levels in crude membrane preparations from dog right atrial tissue before and after AF 
induction.  Example blots are shown in Fig 16 A.  Interestingly, in some samples there was a 
substantial decrease in total TASK-1 signal after AF induction, with an average decrease in pixel 
density from 8797 ± 829 to 3792 ± 1063 (n=10; p<0.005).  However, in the face of this decrease 
in total TASK-1 protein level, there was a large increase in pT383 signal, with an average 
increase in pixel density from 3507 ± 823 to 10452 ± 1161 after induction of POAF (n=10; 
p<0.001).  Because of this variability we separately plotted the total TASK-1 and pT383 TASK-





pattern of changes in expression levels (Fig 16 B).  POAF induction was associated with a 
decrease in total TASK-1 band intensity in tissue from 6/10 dogs, whereas pT383 band intensity 
increased in 9/10 dogs.  When pT383 signal is expressed as a ratio of the total TASK-1 signal, 
the relative amount of pT383 increased from 0.42 ± 0.09 to 5.92 ± 2.07 after AF induction 
(n=10; p<0.05) (Fig 17).  Therefore, the phosphorylation-dependent loss of TASK-1 current in 
POAF correlates to the large increase in phosphorylation at T383, suggesting that 
phosphorylation at this site could be responsible for the inhibition of TASK-1. 
 
Neutrophil myeloperoxidase levels are lower in tissue from dogs with failed POAF 
induction 
In a subset of dogs, surgical and pacing procedures failed to induce sustained AF (N=11/35 
dogs).  In order to determine how inflammation, TASK-1 current inhibition, and T383 
phosphorylation related to the induction of POAF, analyses were repeated on atrial tissue from 
these dogs with failed POAF induction.  Measurement of myeloperoxidase revealed that while 
there was an increase in neutrophil accumulation relative to control tissue (19.5 ± 4.3, n=11 
versus 1.0 ± 0.2; n=17, p<0.001), there was significantly less than in tissue from dogs with 
successful AF induction (36.8 ± 4.8, as described above; p<0.05) (Fig 18).  This indicates that 
failure to induce POAF is associated with a lower level of neutrophil infiltration into atrial tissue 
relative to tissue from dogs with successful POAF induction, and that therefore higher levels of 






TASK-1 current levels in myocytes from dogs with failed POAF induction are similar to 
control 
If the infiltration of neutrophils into atrial myocardium, and the subsequent synthesis of PAF, 
contributes to the inhibition of TASK-1, then one would predict that there would be a lower level 
of TASK-1 inhibition in cells from dogs in which POAF induction was not successful.  Right 
atrial myocytes isolated from the hearts of dogs with failed POAF induction had measurable 
TASK-1 levels (0.44 ± 0.20 pA/pF at +30 mV; n=12 cells from 4 dogs) which were similar to 
control levels (0.45 ± 0.07 pA/pF, as reported above) (Fig 19, right panel).  There were fewer 
cells analyzed in this group, and a higher degree of variation.  In two cells, TASK-1 current 
levels were similar to those found in cells from dogs with successful POAF induction (<0.1 
pA/pF at +30 mV).  In one cell, TASK-1 current levels were much higher than typically 
observed in cells from control pre-operative tissue (>0.5 pA/pF at +30 mV).  The remaining cells 
had TASK-1 current levels that were either similar to control (0.22-0.57 pA/pF at +30 mV; n=7), 
or slightly lower (0.12-0.14 pA/pF at +30 mV; n=2).  Therefore, atrial myocytes from dogs with 
failed POAF induction appear, on average, to be similar to those from pre-operative control 
tissue, but display a larger degree of variation.  In this canine model, the inhibition of TASK-1 
current is associated with the ability to induce POAF, suggesting a possible role for TASK-1 






Total TASK-1 signal decreases and pT383 signal increases after failed AF induction, 
similar to successful AF induction 
Since the level of TASK-1 inhibition in atrial myocytes from dogs with failed induction appears 
similar, on average, to cells from pre-operative control tissue, quantifying the level of 
phosphorylation at T383 was of interest.  Immunoblotting crude membrane extracts from right 
atrial free wall tissue of dogs in which the peri-operative surgery and pacing failed to induce AF 
revealed a similar pattern of total and pT383 TASK-1 expression as seen in tissue from 
successful POAF dogs (Fig 20 A, right panel).  Total TASK-1 levels decreased to various 
degrees peri-operatively, with an average pixel density of 9420 ± 2536 in control atriotomy 
tissue, versus 3439 ± 847 after surgery (n=4; p=0.14).  Phospho-T383 signal increased to various 
degrees peri-operatively, from an average pixel density of 4632 ± 1461 in control atriotomy 
tissue, to 10964 ± 2887 after surgery (n=4; p=0.06) (Fig 20 B).  When expressed as a ratio of 
total TASK-1 band density (to approximate the fraction of TASK-1 phosphorylated at T383), 
pT383 signal increased significantly from an average of 0.51 ± 0.13 in pre-operative control 
tissue to 3.98 ± 1.19 in tissue after failed AF induction (n=4; p<0.05) (Fig 21).  The change in 
the pT383/total TASK-1 ratio (∆ = ratioperi-op - ratiopre-op) was not different in failed AF induction 
versus successful AF induction samples (∆= 3.47 ± 1.23 versus 5.50 ± 2.11; N.S.).  Therefore, 
although the level of TASK-1 inhibition in cells from failed POAF induction experiments was 
similar to pre-operative control, the level of T383 phosphorylation in tissue from failed POAF 
induction experiments was similar to levels in tissue with successful induction of POAF.  
Whereas loss of TASK-1 function tracks with successful AF induction, T383 phosphorylation 





Figure 12: Canine Peri-Operative AF model 
Schematic of the methodology of the canine Peri-Operative AF model.  A.  Atriotomy site and 
placement of pacing and recording leads in canine right atrium.  B.  Timecourse of protocol to 
induce POAF: on Day 0, a 5-cm right atriotomy was performed via a right thoracotomy. Pacing 
and recording electrodes were sutured to the right atrium at this time. Preoperative control tissue 
was trimmed from the atriotomy site for analysis.  On Day 3, the chest was reopened and burst 
pacing was performed to induce AF.  A cardiectomy was performed and post-operative right 






























Figure 13: Induction of AF is associated with an increase in neutrophil accumulation 
Neutrophil myeloperoxidase levels were measured from canine right atrium at the time of 
atriotomy ("Pre-Op Control") or after AF induction ("Peri-Op AF").  Induction of POAF was 






























































Figure 14: TASK-1 is measured as a methanandamide-sensitive difference current in 
isolated atrial myocytes 
Currents from isolated atrial myocytes are measured in a ramp protocol from -50 to +30 mV in 
elevated external K+ to increase the inward component of the current and linearize the I/V curve, 
and in the presence of CsCl, TEA, and nifedipine to block other endogenous currents.  A.  
Typical traces in a human left atrial myocyte shows the total current measured from a cell before 
and after addition of 10 µM methananadamide to the perfusate. B.  The calculated 
methanandamide-sensitive difference current, taken to be TASK-1, displays an I/V relation and 


















Figure 15: TASK-1 is inhibited in a phosphorylation-dependent manner after induction of 
POAF. 
TASK-1 was measured as the methanandamide-sensitive difference current in isolated myocytes 
from right atria of dogs before ("Pre-operative Control," left panel) and after ("Peri-operative 
AF," right panel) the induction of POAF.  A.  Average current densities for cells in each group.  
TASK-1 current (filled circles) was measured in atrial myocytes from pre-operative control 
tissue, but absent in cells from atria of dogs after POAF.  In cells in which the serine/threonine 
phosphatase PP2A was added to the patch pipette (open circles), TASK-1 currents measured in 
pre-operative control tissue were not different from currents in non-PP2A cells.  TASK-1 
currents were restored in PP2A-treated cells from dogs with POAF, to levels no different from 
currents in cells from pre-operative control tissue.   B.  Average TASK-1 current density 
measured at +30 mV described in panel A.  Atrial myocytes from preoperative control tissue had 
0.47 ± 0.10 pA/pF TASK-1 current (n=52 cells from 21 dogs), and cells treated with PP2A had 
similar TASK-1 current levels (0.36 ± 0.05 pA/pF; n=50 cells from 20 dogs).  Right atrial 
myocytes from dogs with POAF had less TASK-1 current (-0.02 ± 0.08 pA/pF at +30 mV; n=19 
cells from 7 dogs; p<0.0001 vs. preoperative control), but cells treated with PP2A had TASK-1 
current levels similar to those in cells from preoperative control tissue (0.27 ± 0.05 pA/pF at +30 















































































Figure 16: Total TASK-1 and pT383 signal before and after induction of POAF. 
Crude membrane fractions of right atrial tissue taken from dogs at the time of atriotomy and after 
induction of POAF were resolved by SDS-PAGE and blotted to nitrocellulose.  Protein was 
visualized using an antibody to total TASK-1 or to pT383 TASK-1, and band densities were 
quantified.  A.  Representative western blots from tissue taken from 5 dogs before ("Pre") or 
after ("Post") induction of POAF, immunoblotted for total TASK-1 (top panel) or pT383 TASK-
1 (bottom panel).  B.  Line graphs demonstrating the change in total TASK-1 (top panel) and 
pT383 TASK-1 (bottom panel) band intensity in tissue from each dog before and after induction 
of POAF, with averages ± SEM.  Induction of POAF was associated with a decrease in TASK-1 
signal in 6/10 dogs, and the average intensity decreased from 8797 ± 829 to 3792 ± 1063 (n=10; 
p<0.005).  Induction of POAF was associated with an increase in pT383 signal in 9/10 dogs, and 









































































Figure 17: Induction of POAF is associated with an increase in relative pT383 signal. 
In order to approximate the relative fraction of TASK-1 that was phosphorylated at T383 before 
and after POAF induction, pT383 signal was expressed as a ratio of total TASK-1 signal.  
Induction of POAF was associated with a significant increase in pT383/TASK-1 ratio, from 0.42 





















































Figure 18: Failed induction of POAF is associated with an intermediate amount of 
neutrophil accumulation in right atrial tissue. 
Neutrophil myeloperoxidase levels in right atrial tissue were measured after surgical and pacing 
protocols failed to induce AF ("Peri-Op Failed Induction") and compared to MPO levels 
previously measured in pre-operative control tissue and tissue from dogs with successful POAF 
induction (see Figure 13).  Myocardium from dogs with failed POAF induction had significantly 
more neutrophil accumulation than pre-operative control tissue (19.5 ± 4.3, n=11 versus 1.0 ± 
0.2; n=17, p<0.001), but significantly less than tissue from dogs with successful POAF induction 








































































Figure 19: TASK-1 is not inhibited after failed induction of POAF. 
TASK-1 was measured as the methanandamide-sensitive current in right atrial myocytes from 
dogs in which surgical and pacing procedures failed to induce POAF, and compared to TASK-1 
current densities observed in cells from pre-operative control tissue or from dogs with successful 
POAF induction (see Figure 15).  A.  Average current densities for cells in each group.  TASK-1 
currents in cells from dogs with failed induction (right panel) were similar to TASK-1 current in 
cells from pre-operative control tissue.  B.  Average TASK-1 current density measured at +30 
mV, as described in panel A.  Cells from dogs with failed induction displayed 0.44 ± 0.20 pA/pF 
TASK-1 (n=12 cells from 4 dogs).  TASK-1 current densities were not significantly different 
from levels seen in cells from preoperative control tissue (0.45 ± 0.07 pA/pF, as reported in 












































































































Figure 20: Total and pT383 TASK-1 levels before and after failed induction of POAF. 
Crude membrane fractions of right atrial tissue taken from pre-operative control tissue and from 
dogs after surgery and pacing protocols failed to induce POAF were resolved by SDS-PAGE and 
blotted to nitrocellulose.  Protein was visualized using an antibody to total TASK-1 or to pT383 
TASK-1, and band densities were quantified and compared to band densities observed in tissue 
from dogs with successful POAF induction.  A.  Representative western blots of tissue taken 
before ("Pre")  and after ("Post") surgery and pacing failed to induce POAF (right panel), 
immunoblotted for total TASK-1 (top) and pT383 TASK-1 (bottom).  Also shown are the 
representative western blots of tissue from dogs with successful POAF induction (left panel), 
previously shown in Figure 16.  B.  Line graphs demonstrating the change in total TASK-1 (top 
panel) and pT383 TASK-1 (bottom  panel) band intensity from dogs with successful POAF 
induction (black lines) and failed POAF induction (red lines), and the respective pre-operative 
and peri-operative average band intensity ± SEM.  Total and pT383 TASK-1 signal levels in 
tissue from dogs with failed POAF induction were similar to levels in tissue from dogs with 
successful POAF induction, with an average total TASK-1 band intensity tending to decrease 
(but not significantly) from 9420 ± 2536 to 3439 ± 847 (n=4, p=0.14), and pT383 band intensity 
































































Figure 21: Failed induction of POAF is associated with an increase in pT383 signal, 
indistinguishable from pT383 signal from tissue from dogs with successful POAF 
induction. 
In order to approximate the relative fraction of TASK-1 that was phosphorylated at T383 before 
and after surgery and pacing protocols failed to induce POAF, pT383 signal was expressed as a 
ratio of total TASK-1 signal.  Failure to induce POAF (right panel) was associated with a 
significant increase in pT383/TASK-1 ratio, from 0.51 ± 0.13 to 3.98 ± 1.19 (n=4; p=0.03).  This 
increase in pT383/TASK-1 ratio was indistinguishable from the increase seen in tissue from dogs 




























































Chapter 4.2: Chronic AF in the canine rapid-pacing model 
After studying canine POAF as an acute model of atrial fibrillation (i.e. initiation of the 
arrhythmia), chronic atrial fibrillation (i.e. maintenance of the arrhythmia), was studied in canine 
rapid-pacing AF.  In order to determine if chronic AF was associated with neutrophil infiltration, 
phosphorylation-dependent TASK-1 inhibition, and phosphorylation of TASK-1 at T383, 
analyses were repeated in tissue from this models. 
In canine rapid-pacing AF, rapid atrial pacing is performed in canines for 4-6 weeks.  
Successful induction of AF occurs when pacing is stopped, but the arrhythmia is maintained for 
at least 5 days.  A group of “sham” animals is implanted with nonfunctional pacing electrodes, 
and thus maintain a normal physiological heart rate throughout the experiments (Fig 22).  
Animal were sacrificed and tissue was analyzed 4-6 weeks after pacing protocols began, and 6-8 
weeks after the initial surgery to implant pacemakers.   
 
Levels of neutrophil accumulation are unchanged in chronic rapid-pacing AF 
Right atrial tissue from dogs with chronic AF after rapid-pacing protocols did not have 
significantly more neutrophil myeloperoxidase activity (0.72 ± 0.54 units/gram; n=4) than sham 
dogs, which were operated on and instrumented, but whose atria were not paced and therefore 
maintained a normal heart rate (0.33 ± 0.07 units/gram; n=4; p=0.52) (Fig 23).  Using the 
calibration calculated earlier, this corresponds to 1.25 ± 0.94 x 106 neutrophils per gram of tissue 
from dogs in AF, and 0.57 ± 0.12 x 106 neutrophils per gram of tissue from sham-operated dogs.  





(36.8 ± 4.8 units MPO/gram, or 63.8 ± 8.4 x 106 neutrophils/gram, as described above).  
Therefore, this period of sustained AF is not associated with an increased level of neutrophil 
influx into atrial myocardium.  
 
Chronic rapid-pacing AF results in a phosphorylation-dependent loss of TASK-1 current 
in canine atrial myocytes 
In order to determine whether TASK-1 current inhibition was associated with this model 
of atrial fibrillation, even in the absence of neutrophil infiltration, TASK-1 currents were 
measured in cells from dogs with rapid-pacing AF.  TASK-1 current levels were measured as the 
methanandamide-sensitive difference current in right atrial myocytes from unoperated control, 
sham-paced, and rapid-paced AF dogs.  TASK-1 current levels from sham-paced canine atrial 
myocytes (0.25 ± 0.03 pA/pF at +30 mV; n=3 cells from 1 dog) were not different from control 
(0.33 ± 0.05 pA/pF at +30 mV; n=9 cells from 3 dogs).  However, in cells from dogs with AF, 
TASK-1 currents were absent (0.005 ± 0.04 pA/pF at +30 mV; n=5 cells from 3 dogs, p<0.001) 
(Fig 24, filled circles).  Whereas addition of PP2A to the patch pipette had no effect on the level 
of TASK-1 current measured in cells from control dogs (0.2 ± 0.04; n=7 cells from 3 dogs), or 
sham-paced dogs (0.2 ± 0.04; n=6 cells from 1 dog), TASK-1 currents were partially restored in 
cells from AF dogs in which PP2A was added to the patch pipette (0.1 ± 0.03 pA/pF at +30 mV; 
n=10 cells from 3 dogs) (Fig 24, open circles).  Therefore, a phosphorylation-dependent loss of 






There is no increase in T383 phosphorylation in canine chronic rapid-pacing AF 
To determine whether phosphorylation at T383 could be associated with the 
phosphorylation-dependent loss of TASK-1 current observed in cells from dogs with sustained 
rapid-pacing AF, SDS-PAGE followed by immunoblot analysis was performed on crude 
membrane preparations of atrial tissue from dogs in this model.  Western blot analysis was 
performed on sham-paced, rapid-paced AF, or control dogs, and bands were detected using an 
antibody for total TASK-1 signal and the pT383 PSSA (Fig 25A).  There was no difference in 
the total TASK-1 signal between tissue from dogs with AF and sham-paced dogs (8991 ± 532 vs 
8601 ± 299 pixels; N.S.), although both groups had a significantly higher level of TASK-1 than 
tissue from unoperated controls (6556 ± 624; p<0.05) (Fig 25B, left panel).  There was no 
significant difference in the levels of pT383 signal between tissue from control dogs (2026 ± 516 
pixels), sham-paced dogs (2450 ± 867 pixels), or dogs with AF (2738 ± 777) (Fig 25B, right 
panel).  To approximate the proportion of TASK-1 channels phosphorylated at T383, pT383 
band intensity was expressed as a ratio of total TASK-1 band intensity.  Relative pT383 signal 
was not different in tissue lysates from dogs with AF (0.31 ± 0.09; n=7) versus tissue lysates 
from sham-paced (0.29 ± 0.11; n=6) or unoperated control (0.33 ± 0.08; n=5) dogs (N.S.) (Fig 
25C).  Therefore, at the timepoint in the sustained arrhythmia at which tissue was collected, 
phosphorylation at T383 is not associated with chronic AF, and does not appear to be responsible 






Figure 22: Rapid Pacing model of chronic canine AF. 
Schematic of the methodology of the canine rapid pacing model of chronic AF.  A.  Ablation of 
the His bundle and placement of pacing leads on the right ventricle free wall and right atrial 
appendage.  "Sham" dogs were implanted with nonfunctioning right atrial leads.  Picture adapted 
from Gray, 1918 (Fig 501).  B.  Timecourse of protocol to induce chronic AF: atrioventricular 
block was achieved by ablation of the His bundle, and ventricles of all animals were paced at a 
normal physiological rate (NPR) from the right ventricular free wall for the remainder of the 
experiment.  Atria of "sham" dogs were not paced, and atrial rate was determined by the sinus 
node.  This physiological rate was maintained for an additional 50 days before sacrifice.  Atria of 
"AF" dogs were paced at NPR for two weeks of recovery.  AF was induced in dogs by the rapid 
pacing of right atrial for 4-6 weeks.  AF was successful when maintained for >5 days in the 

































Figure 23: Chronic AF in a canine rapid pacing model is not associated with increased 
myeloperoxidase levels. 
Neutrophil myeloperoxidase levels were measured in right atrial tissue from dogs with sustained 
AF induced by rapid pacing, and from sham-paced dogs.  Sustained AF was not associated with 
an increase in neutrophil accumulation (0.72 ± 0.54 units/gram; n=4) relative to sham-pacing 
(0.33 ± 0.07 units/gram; n=4; p=0.52).  MPO levels in tissue from both groups of dogs were 
lower than MPO levels previously seen in tissue after induction of POAF (see Figure 13).  Bars 


























































Figure 24: TASK-1 is inhibited in a phosphorylation-dependent manner in right atrial 
myocytes from dogs with chronic AF. 
TASK-1 was measured as the methanandamide-sensitive current in right atrial myocytes isolated 
from unoperated control (left panel) and sham-paced (center panel) dogs, and from rapid-paced 
dogs with sustained AF (left panel).   A.  Average TASK-1 I/V relations from cells in each 
group.  TASK-1 current was present (filled circles) in cells from unoperated control dogs (n=11 
cells from 4 dogs) and from sham-paced dogs (n=3 cells from 1 dog).  TASK-1 current was 
absent in cells from dogs with AF (n=5 cells from 3 dogs, p<0.001 versus cells from normal 
control dogs).  In cells from unoperated control dogs (n=9 cells from 4 dogs) and from sham-
paced dogs (n=6 cells from 1 dog) in which PP2A was added to the patch pipette, TASK-1 were 
similar to levels in non-PP2A-treated cells.  In cells from dogs with AF in which PP2A was 
added to the patch pipette (open circles), TASK-1 current was present (n=10 cells from 3 dogs).  
B.   Average TASK-1 current density measured at +30 mV, as described in panel A.  Error bars 















































































Figure 25: Chronic rapid-pacing AF is not associated with an increase in relative pT383 
levels. 
Crude membrane fractions of right atrial tissue taken from unoperated control and sham-paced 
dogs, and from dogs with sustained AF, were resolved by SDS-PAGE and blotted to 
nitrocellulose.  Protein was visualized using an antibody to total TASK-1 or to pT383 TASK-1, 
and band densities were quantified.  A.  Representative western blots of tissue taken from 
unoperated control dogs, sham-paced dogs, and dogs with AF immunoblotted for total TASK-1 
(top) and pT383 TASK-1 (bottom).  B.  Average total TASK-1 band intensity (left panel) of 
tissue from unoperated control dogs (6556 ± 624 pixels, n=5), sham-paced dogs (8601 ± 299 
pixels, n=6), and dogs with AF (8991 ± 532 pixels, n=7).  TASK-1 levels in tissue from sham-
paced dogs and dogs with AF were significantly higher than in tissue from unoperated control 
dogs (p=0.0102).  Average pT383 band intensity (right panel) of tissue from unoperated control 
dogs (2026 ± 516 pixels), sham-paced dogs (2450 ± 867 pixels), and dogs with AF (2738 ± 777).   
There were no significant differences in pT383 signal between groups.  C.  Average pT383 band 
intensity, normalized to total TASK-1 band intensity, for the three groups.  There were no 
differences in the pT383/TASK-1 ratio between control dogs (0.33 ± 0.08), sham-paced dogs 
































































































Chapter 4.3: Chronic AF in human patients 
After determining that TASK-1 inhibition was associated with the initiation of acute 
POAF and with chronic AF in canine models, it remained to be determined whether TASK-1 
inhibition was also associated with the human disease.  Left atrial free wall tissue was collected 
from human patients undergoing valve repair surgery with or without a history of AF. 
 
Human Patient Population 
The characteristics of the total patient population are listed in Table 1.  Data regarding 
patient age, sex, AF diagnosis, left ventricular ejection fraction, and drug therapy was available 
for every sample collected.  Left atrial diameter data was available for 57 out of the 71 total 
patients (28/36 NSR and 29/35 AF).  As expected, patients with AF tended to be taking more 
medications than their counterparts in NSR, particularly the anticoagulant coumadin 
(p=<0.0001), the cardiotonic digoxin (p<0.001) and β blockers (p=<0.001).  In general, patients 
with AF were older (p<0.001), consisted of a higher proportion of females (p<0.05), and had 
increased left atrial dilation (p<0.0001).  According to the criteria of the American Society of 
Echocardiography (Lang et al, 2005), 18% of patients in NSR had normal left atrial diameters, 
21% had mild dilation, 29% had moderate dilation, and 32% had severe dilation.  No patients 
with AF had normal left atrial diameters, 10% had mild dilation, 10% had moderate dilation, and 
79% had severe dilation. 
To ensure that age and sex were not confounding factors, myeloperoxidase and 





summarized in Table 2 and Table 3, respectively, and immunoblotting analyses were performed 
both on a large population (Table 4), and on an age-limited subset of patients (Table 5).    
 
Neutrophil levels are not elevated in human chronic AF 
Neutrophils have been shown to be associated with the initiation of POAF in our canine 
model, and have been implicated in the initiation of the arrhythmia in human POAF (Baker and 
White, 2007; Fontes et al, 2005).  In order to determine whether there was an increase in 
neutrophil infiltration into atrial myocardium associated with chronic AF in humans, left atrial 
free wall tissue was collected from human patients undergoing mitral valve repair surgery with 
or without a history of atrial fibrillation.  Clinical characteristics of the 9 patients in NSR and 9 
patients with AF are summarized in Table 2.  There were no statistical differences in the age or 
sex of the two groups of patients.  Neutrophil accumulation did not differ in tissue from patients 
with AF (0.99 ± 0.46 units/gram) compared to those in normal sinus rhythm (0.76 ± 0.17 
units/gram; p=0.64) (Fig 26), and MPO levels from both groups were substantially lower than 
those found in canine POAF tissue (36.8 ± 4.8 units/gram, as discussed in Chapter 4.1).  
Therefore, chronic human AF is not associated with an increase in neutrophil infiltration into 
atrial myocardium. 
 
TASK-1 current is inhibited in a phosphorylation-dependent manner in human AF 
To determine whether TASK-1 was inhibited in cells from patients with AF, despite the 





methanandamide-sensitive difference current in left atrial free wall myocytes from tissue from 
human patients in normal sinus rhythm and from patients with a history of AF.  The age and sex 
of patients with AF and in NSR were not different, as summarized in Table 3.  TASK-1 current 
was present in cells from patients in NSR (0.36 ± 0.06 pA/pF at +30 mV; 10 cells from 6 
patients), but was absent in cells from patients with AF (0.002 ± 0.04 pA/pF at +30 mV; 9 cells 
from 5 patients) (Fig 27, filled circles).  In some cells from patients with AF, PP2A was added to 
the patch pipette, resulting in TASK-1 current levels indistinguishable from levels in cells from 
patients in NSR (0.45 ± 0.16 pA/pF at +30 mV; 13 cells from 4 patients).  Addition of PP2A to 
cells from patients in NSR had no effect on the level of TASK-1 current measured (0.32 ± 0.08 
pA/pF at +30 mV; 8 cells from 5 patients) (Fig 27, open circles).  Therefore there is a 
phosphorylation-dependent inhibition of TASK-1 associated with human AF. 
 
There is no increase in T383 phosphorylation in human chronic AF  
To determine whether an increase in phosphorylation at T383 could contribute to the 
phosphorylation-dependent loss of hTASK-1 current seen in atrial myocytes from patients with 
AF, western blot analysis was performed on crude membrane preparations of left atrial free wall 
tissue from 21 patients in NSR and 19 patients with AF.  Characteristics of the two patient 
groups are summarized in Table 4.  Equal protein was loaded and total and pT383 TASK-1 
signal was measured (Fig 28 A).  There was no difference in total TASK-1 pixel density between 
NSR and AF patient groups (8250 ± 3025 vs. 8091 ± 2875; p=0.8657).  When expressed as a 





there was no significant difference in relative pT383 signal between patients in NSR and patients 
with AF (1.79 ± 0.51 vs. 1.53 ± 0.47) (Fig 28 B).   
Since age and sex differed significantly between the two populations, it was possible that 
either characteristic could be a confounding factor, masking a potential difference in total or 
pT383 TASK-1 signal between groups.  Therefore, a separate analysis was performed only on 
patients 53-71 years of age.  The characteristics of this subset of 13 patients in NSR and 10 
patients with AF are summarized in Table 5.  Eliminating very young and very old patients from 
the analysis corrected the previous age difference observed between groups in the western blot 
population as a whole.  There was also no significant difference in sex between groups, likely 
due to the exclusion of very old patients in which females are overrepresented.  In this age-
matched subset, there was still no difference in total TASK-1 pixel density between the two 
patient groups (8954 ± 832 in NSR versus 7494 ± 607 in AF; N.S).  When expressed as a ratio to 
total TASK-1 signal, there was similarly no significant difference in relative pT383 signal 
between patients in NSR and patients with AF (1.80 ± 0.10 versus 1.57±0.17; N.S.) (Fig 28 C).   
Although direct comparisons between the TASK-1 and pT383 TASK-1 levels of tissue 
from human versus canine atrium were never made within the same western blots, identical 
antibody concentrations and similar exposure times suggest that pT383 signal is higher in crude 
membrane preparations from human patients than from canine models.  The pT383 signal is 
strong in immunoblots from human patients in NSR and with AF (Fig 28 A), whereas signal 
appeared weak in pre-operative control tissue and in atrial tissue from sham and rapid-pacing AF 
model dogs.  However, there is no further increase in phosphorylation at T383 associated with 





responsible for the phosphorylation-dependent loss of TASK-1 current observed in chronic AF in 
human patients. 
 
The findings from Chapters 4.1-4.3, comparing neutrophil accumulation, TASK-1 current 
levels, and T383 phosphorylation in human AF and the two canine models of AF are 
summarized in Table 6.  Although neutrophil accumulation and increased phosphorylation of 
T383 are only associated with POAF, there is a phosphorylation-dependent inhibition of TASK-





Figure 26: Human AF is not associated with an increase in neutrophil accumulation in left 
atrial tissue. 
Myeloperoxidase levels were measured in left atrial free wall tissue from human valve repair 
patients in NSR or with AF.  AF was not associated with an increase in neutrophil infiltration 






















































Figure 27: TASK-1 current is inhibited in a phosphorylation-dependent manner in cells 
from human patients with AF. 
TASK-1 was measured as the methanandamide-sensitive current in left atrial myocytes isolated 
from human patients in NSR (left panel) or with AF (right panel).  A.  Average I/V relation from 
cells in each group.  TASK-1 current was present (filled circles) in cells from patients in NSR 
(n=10 cells from 6 patients), but was absent in cells from patients with AF (n=9 cells from 5 
patients; p<0.01 vs. NSR).  In cells from patients in NSR in which PP2A was added to the patch 
pipette (open circles), TASK-1 currents were similar to those observed in non-PP2A-treated cells 
(n=8 cells from 5 patients).   In cells from patients with AF in which PP2A was added to the 
patch pipette, TASK-1 current was rescued to levels similar to those seen in cells from patients 
in NSR (n=13 cells from 4 patients).  B.   Average TASK-1 current density measured at +30 mV, 



























































Figure 28: AF is not associated with a change in total TASK-1 or in relative pT383 signal in 
left atrial tissue from human patients. 
Crude membrane fractions of left atrial tissue taken from human valve repair patients in NSR or 
with AF were resolved by SDS-PAGE and blotted to nitrocellulose.  Protein was visualized 
using an antibody to total TASK-1 or to pT383 TASK-1, and band densities were quantified     
A.  Representative western blots of tissue from patients in NSR or with AF immunoblotted for 
total TASK-1 (top) and pT383 TASK-1 (bottom).  B.  There is no difference in average total 
TASK-1 band intensity (left panel) of tissue from all patients in NSR (n=21) versus all patients 
with AF (n=19).  There is also no difference in the ratio of pT383/total TASK-1 band intensity 
(right panel) of tissue from all patients in NSR versus all patients in AF.  C.  In an age-matched 
subset of patients, there was likewise no difference between patients in NSR versus patients with 
AF in total TASK-1 band intensity (n=13 NSR, n=10 AF) or the ratio of pT383/total TASK-1 















































































































Table 1: Patient Characteristics: Combined Populations 
Characteristic NSR Group             
(N = 36) 
AF Group          
(N = 35) 
p-value 
Age – mean (SEM) 52.7  (2.8)  66.6  (2.7) 0.0065 
 Male – no. (%)       25  (69.4)       15  (42.9) 0.0321 
 Ejection Fraction – % (SEM) 52.3  (1.9)  48.9  (1.9) 0.2144 
 Left Atrium Diameter – cm (SEM)   4.72  (0.15)    5.82  (0.19) <0.0001 
 Surgery Performed – no. (%)    
     MAZE      0  (0.0)       23  (88.6) <0.0001 
     MVR      35  (97.2)       23  (65.7) 0.1987 
     AVR      2  (5.6)        5  (14.3) 0.2603 
     TVR      2  (5.6)        5  (14.3) 0.2603 
     CABG        8  (22.2)        9  (25.7) 0.7861 
     PFO Closure       2  (5.6)      0  (0.0) 0.4930 
     Ventricular Aneurism Plication       1  (2.8)      0  (0.0) 1.0000 
     Thrombectomy       0  (0.0)      1  (2.9) 0.4930 
     LA Appendage Resection       0  (0.0)      1  (2.9) 0.4930 
     ASD Repair       1  (2.8)      0  (0.0) 1.0000 
Medications – no. (%)    
     β-blockers      15  (41.7)      26  (74.3) 0.0080 
     Coumadin        4  (11.1)      27  (77.1) <0.0001 
     Diuretics       11  (30.6)      18  (51.4) 0.0935 
     Statins and other cholesterol 
meds 
      16  (44.4)      16  (45.7) 1.0000 
     Digoxin         4  (11.1)      14  (40.0) 0.0066 
     ASA         8  (50.0)      11  (31.4) 0.1488 
     ACE inhibitor        11  (30.6)      11  (31.4) 1.0000 
     ATII Receptor Angatonists       14  (38.9)        9  (25.7) 0.3121 
     Amiodarone       1  (2.8)        4  (11.4) 0.1987 
     Calcium Channel Blockers         4  (11.1)        6  (17.1) 0.5141 
     Sodium Channel Blockers       0  (0.0)      2  (5.7) 0.2394 
     Diabetes Medications         4  (11.1)      1  (2.9) 0.3570 
     Antihistamine       3  (8.3)        4  (11.4) 0.7170 
     Antacid/Proton Pump Inhibitor         9  (25.0)        7  (20.0) 0.7775 
     Antidepressant/Hypnotic        5  (13.9)        4  (11.4) 1.0000 
     Gout Medications        6  (16.7)      2  (5.7) 0.2603 
     Corticosteroids      3  (8.3)      2  (5.7) 1.0000 
     Plavix      3  (8.3)      2  (5.7) 1.0000 
     Alpha Blockers/BHP 
Medications 





Table 2: Patient Characteristics: Myeloperoxidase Analysis 
Characteristic NSR Group             
(N = 9) 
AF Group          
(N = 9) 
p-value 
Age – mean (SEM) 66.8  (4.0)  74.4  (3.1) 0.1532 
Male – no. (%)        5  (55.6)        4  (44.4) 1.0000 
Ejection Fraction – % (SEM) 57.2  (2.2)  49.7  (2.2) 0.0297 
Left Atrium Diameter – cm (SEM)   5.13  (0.30)    6.04  (0.31) 0.0576 
Surgery Performed – no. (%)    
     MAZE      0  (0.0)        5  (55.6) 0.0294 
     MVR      9  (100)        7  (77.8) 0.4706 
     AVR      0  (0.0)        1  (11.1) 1.0000 
     TVR       1  (11.1)        1  (11.1) 1.0000 
     CABG       1  (11.1)        3  (33.3) 0.5765 
     PFO Closure      0  (0.0)       0  (0.0)  
     Ventricular Aneurism Plication      0  (0.0)       0  (0.0)  
     Thrombectomy      0  (0.0)       0  (0.0)  
     LA Appendage Resection      0  (0.0)       0  (0.0)  
     ASD Repair      0  (0.0)       0  (0.0)  
Medications – no. (%)    
     β-blockers        3  (33.3)       8  (88.9) 0.0498 
     Coumadin        1  (11.1)       8  (88.9) 0.0034 
     Diuretics        3  (33.3)       5  (55.6) 0.6372 
     Statins and other cholesterol        4  (44.4)       4  (44.4) 1.0000 
     Digoxin        1  (11.1)       3  (33.3) 0.5765 
     ASA        3  (33.3)       3  (33.3) 1.0000 
     ACE inhibitor        3  (33.3)       4  (44.4) 0.6250 
     ATII Receptor Angatonists        3  (33.3)       2  (22.2) 1.0000 
     Amiodarone       0  (0.0)      0  (0.0)  
     Calcium Channel Blockers        1  (11.1)       2  (22.2) 1.0000 
     Sodium Channel Blockers       0  (0.0)       1  (11.1) 1.0000 
     Diabetes Medications        1  (11.1)       1  (11.1) 1.0000 
     Antihistamine       0  (0.0)      0  (0.0)  
     Antacid/Proton Pump Inhibitor        1  (11.1)       3  (33.3) 0.5765 
     Antidepressant/Hypnotic        1  (1.11)       1  (11.1) 1.0000 
     Gout Medications        1  (11.1)       2  (22.2) 1.0000 
     Corticosteroids       0  (0.0)      0  (0.0)  
     Plavix        2  (22.2)       2  (22.2) 1.0000 





Table 3: Patient Characteristics: Electrophysiological Recordings 
Characteristic NSR Group             
(N = 8) 
AF Group         
(N = 5) 
p-value 
Age – mean (SEM) 57.6  (4.4)  60.2  (10.2) 0.7949 
Male – no. (%)        5  (62.5)       2  (40.0) 0.5921 
Ejection Fraction – % (SEM) 49.8  (4.7)  53.0  (6.4) 0.4563 
Left Atrium Diameter – cm (SEM)   4.40  (0.28)    5.08  (0.24) 0.1123 
Surgery Performed – no. (%)    
     MAZE      0  (0.0)        3  (60.0) 0.0008 
     MVR       7  (87.5)       5  (100) 1.0000 
     AVR       2  (25.0)       0  (0.0) 0.4872 
     TVR       1  (12.5)       0  (0.0) 1.0000 
     CABG       1  (12.5)        1  (20.0) 1.0000 
     PFO Closure       1  (12.5)       0  (0.0) 1.0000 
     Ventricular Aneurism Plication       1  (12.5)       0  (0.0) 1.0000 
     Thrombectomy      0  (0.0)       0  (0.0)  
     LA Appendage Resection      0  (0.0)       0  (0.0)  
     ASD Repair      0  (0.0)       0  (0.0)  
Medications – no. (%)    
     β-blockers       2  (25.0)        2  (40.0) 1.0000 
     Coumadin       1  (12.5)        4  (80.0) 0.0319 
     Diuretics       2  (25.0)        1  (20.0) 1.0000 
     Statins and other cholesterol       3  (37.5)        1  (20.0) 1.0000 
     Digoxin      0  (0.0)        2  (40.0) 0.1282 
     ASA       4  (50.0)       0  (0.0) 0.1049 
     ACE inhibitor        1  (12.5)        1  (20.0) 1.0000 
     ATII Receptor Angatonists        4  (50.0)        1  (20.0) 0.5649 
     Amiodarone       0  (0.0)        1  (20.0) 0.3846 
     Calcium Channel Blockers         1  (12.5)        1  (20.0) 1.0000 
     Sodium Channel Blockers       0  (0.0)        1  (20.0) 0.3846 
     Diabetes Medications         2  (25.0)       0  (0.0) 0.4872 
     Antihistamine        0  (0.0)       0  (0.0)  
     Antacid/Proton Pump Inhibitor         3  (37.5)        1  (20.0) 1.0000 
     Antidepressant/Hypnotic        1  (12.5)        1  (20.0) 1.0000 
     Gout Medications        2  (25.0)       0  (0.0) 0.4872 
     Corticosteroids       0  (0.0)       0  (0.0)  
     Plavix       0  (0.0)       0  (0.0)  





Table 4: Patient Characteristics: Western Blot Analysis 
Characteristic NSR Group             
(N = 19) 
AF Group         
(N = 21) 
p-value 
Age – mean (SEM) 58.9  (2.4) 68.8  (2.6) 0.0089 
Male – no. (%)      15  (78.9)       9  (42.9) 0.0270 
Ejection Fraction – % (SEM) 51.9  (3.0)  47.5  (2.6) 0.2767 
Left Atrium Diameter – cm (SEM)   4.63  (0.19)    5.95  (0.27) 0.0009 
Surgery Performed – no. (%)    
     MAZE        0  (0.0)       15  (71.4) <0.0001 
     MVR       19  (100)       19  (90.5) 0.4885 
     AVR        0  (0.0)        4  (19.0) 0.1079 
     TVR        0  (0.0)        4  (19.0) 0.1079 
     CABG         6  (31.6)        5  (23.8) 0.7271 
     PFO Closure        1  (5.3)       0  (0.0) 0.4750 
     Ventricular Aneurism Plication        0  (0.0)       0  (0.0)  
     Thrombectomy        0  (0.0)       1  (4.8) 1.0000 
     LA Appendage Resection        0  (0.0)       1  (4.8) 1.0000 
     ASD Repair        1  (5.3)       0  (0.0) 0.4750 
Medications – no. (%)    
     β-blockers         10  (52.6)       16  (76.2) 0.1856 
     Coumadin          2  (10.5)       15  (71.4) 0.0001 
     Diuretics          6  (31.6)       12  (57.1) 0.1253 
     Statins and other cholesterol          9  (47.4)       11  (52.4) 1.0000 
     Digoxin          3  (15.8)        9  (42.9) 0.0888 
     ASA         11  (57.9)        8  (38.1) 0.3419 
     ACE inhibitor          7  (36.8)        6  (28.6) 0.7378 
     ATII Receptor Angatonists          7  (36.8)        6  (28.6) 0.3121 
     Amiodarone         1  (5.3)        3  (14.3) 0.6071 
     Calcium Channel Blockers          2  (10.5)        3  (14.3) 1.0000 
     Sodium Channel Blockers         0  (0.0)       0  (0.0)  
     Diabetes Medications          1  (5.31)       0  (0.0) 0.4750 
     Antihistamine          3  (15.8)        4  (19.0) 1.0000 
     Antacid/Proton Pump Inhibitor          5  (26.3)        3  (14.3) 0.4420 
     Antidepressant/Hypnotic          3  (15.8)       2  (9.5) 0.6544 
     Gout Medications          3  (15.8)       0  (0.0) 0.0981 
     Corticosteroids          3  (15.8)       2  (9.5) 0.6544 
     Plavix         1  (5.3)       2  (5.7) 1.0000 





Table 5: Patient Characteristics: Western Blot Analysis - Age Matched Subset 
Characteristic NSR Group             
(N = 13) 
AF Group         
(N = 10) 
p-value 
Age – mean (SEM) 60.6  (1.9) 59.6  (1.8) 0.7068 
Male – no. (%)       10  (76.9)       7  (70.0) 1.0000 
Ejection Fraction – % (SEM)  53.7  (3.3)  45.3  (3.7) 0.1008 
Left Atrium Diameter – cm (SEM)   4.74  (0.26)    6.06  (0.44) 0.0207 
Surgery Performed – no. (%)    
     MAZE       0  (0.0)       6  (60.0) 0.0021 
     MVR      13  (100)       9  (90.0) 0.4348 
     AVR       0  (0.0)       1  (10.0) 0.4348 
     TVR       0  (0.0)       3  (30.0) 0.0678 
     CABG        4  (30.8)       3  (30.0) 1.0000 
     PFO Closure       1  (7.7)      0  (0.0) 1.0000 
     Ventricular Aneurism Plication       0  (0.0)      0  (0.0)  
     Thrombectomy       0  (0.0)       1  (10.0) 0.4348 
     LA Appendage Resection       0  (0.0)      0  (0.0)  
     ASD Repair       1  (7.7)      0  (0.0) 1.0000 
Medications – no. (%)    
     β-blockers        5  (38.5)      7  (70.0) 0.2138 
     Coumadin       1  (7.7)      7  (70.0) 0.0059 
     Diuretics        4  (30.8)      6  (60.0) 0.2215 
     Statins and other cholesterol        5  (38.5)      6  (60.0) 0.4136 
     Digoxin        2  (15.4)      3  (30.0) 0.6175 
     ASA        8  (61.5)      5  (50.0) 0.6850 
     ACE inhibitor        4  (30.8)      5  (50.0) 0.4173 
     ATII Receptor Angatonists        5  (38.5)      1  (10.0) 0.1790 
     Amiodarone       0  (0.0)      1  (10.0) 0.4348 
     Calcium Channel Blockers         2  (15.4)      2  (20.0) 1.0000 
     Sodium Channel Blockers       0  (0.0)     0  (0.0)  
     Diabetes Medications       1  (7.7)     0  (0.0) 1.0000 
     Antihistamine         3  (23.1)      1  (10.0) 0.6036 
     Antacid/Proton Pump Inhibitor         3  (23.1)     0  (0.0) 0.2292 
     Antidepressant/Hypnotic         2  (15.4)     0  (0.0) 0.4862 
     Gout Medications         3  (23.1)     0  (0.0) 0.2292 
     Corticosteroids         2  (15.4)      1  (10.0) 1.0000 
     Plavix        1  (7.7)     0  (0.0) 1.0000 




















Neutrophil Infiltration? ++ + - - 
Increase in T383 
Phosphorylation? 
+ + - - 
Loss of TASK-1 Current? + - + + 
TASK-1 Inhibition is 
Phosphorylation-
Dependent? 






CHAPTER 5: DISCUSSION 
 
Overview 
This study has identified threonine-383 in the C-terminal tail of human TASK-1 as a 
phosphorylation site that is critical to the regulation of channel function.   Furthermore, 
investigations have been carried out to explore the link between the phosphorylation of this 
residue and the development of acute or chronic models of atrial fibrillation. 
Previous work had identified phosphorylation of T381 in the murine TASK-1 channel as 
a site necessary for the inhibition of mTASK-1 downstream of PAFR and PKCε signaling 
(Besana et al, 2004).  Activated neutrophils, and the proinflammatory signaling lipid, PAF, 
synthesized by neutrophils, prolong the APD and induce early after depolarizations in isolated 
myocytes.  Signaling downstream of the PAFR, or direct activation of PKCε, inhibits TASK-1 
and induces similar action potential abnormalities in isolated mouse ventricular myocytes.  
However, studies of arrhythmias in mice are not ideal, due to the very short APD and relative 
resistance to reentry.  In order to study the role of TASK-1 phosphorylation in higher mammals, 
in which the most established arrhythmia models have been developed, the phosphorylation site 
analogous to the murine T381 had to be determined in canine or human channels.  The distal 
portion of the TASK-1 C-terminus, in which putative phosphorylation sites were studied, is 
highly homologous in the canine and human channel, containing identical putative PKC 





Experiments in this thesis have identified T383 in hTASK-1 as a target phosphorylation 
site downstream of PKCε or PAF signaling.  This site is phosphorylated directly by PKCε in 
vitro, and is phosphorylated downstream of PAFR signaling in heterologous cell expression 
systems and in native canine atrial tissue.  The PAF-dependent phosphorylation at T383 in atrial 
tissue was further shown to be PKC-dependent.  The known pro-inflammatory effects of PAF, as 
well as the action potential abnormalities observed after direct TASK-1 inhibition by 
methanandamide in isolated mouse ventricular myocytes (Barbuti et al, 2002), suggested that the 
inhibitory phosphorylation at T383 could play a role in arrhythmias, particularly those with an 
inflammatory component to their etiology.  
This work has elucidated an association between phosphorylation-dependent loss of 
TASK-1 current and atrial fibrillation.  TASK-1 current is absent in cells from three instances of 
AF: a canine model of peri-operative AF, a rapid-pacing canine model of sustained AF, and cells 
from human patients with chronic AF.  In each case, the current can be rescued with phosphatase 
treatment, confirming that the current loss is phosphorylation-dependent.  In canine peri-
operative AF, the loss of TASK-1 current coincides with a significant increase in 
phosphorylation of T383 as measured by the immunoblot signal obtained with a pT383 
phosphorylation site-specific antibody.  In addition, in canine POAF, there is a marked increase 
in neutrophil infiltration into the atrial myocardium consistent with an increase in PAF signaling 
leading to the channel phosphorylation. 
In the POAF model, a small number of dogs undergo the surgical and pacing protocols 
but cannot be induced to sustain AF.  In these animals, neutrophil infiltration is lower than in 





is not different from pre-operative control cells and yet the pT383 levels increase.  Possible 
explanations for this apparent discrepancy will be discussed below. 
In a canine rapid-pacing model of sustained AF, the animal is subjected to atrial 
tachycardic pacing for 4-6 weeks.  Successful induction of AF occurs when the pacing is stopped 
and the arrhythmia is maintained for at least 5 days.  In the atrium of these dogs, there is no 
increase in myocardial neutrophil accumulation at the time of euthanasia, probably indicating 
that the time of peak neutrophil infiltration (which is expected to resolve within days of tissue 
injury) has passed.  The phosphorylation-dependent loss of TASK-1 current from cells taken at 
this time does not correlate with a change in pT383 levels.  Similarly, human patients with 
chronic AF do not demonstrate a higher level of myocardial neutrophil accumulation relative to 
patients in NSR, and the phosphorylation-dependent loss of TASK-1 current from isolated atrial 
myocytes again does not correlate with a change in pT383 levels.  The association between AF, 
neutrophil infiltration into the myocardium, TASK-1 current inhibition, and phosphorylation at 
T383 is summarized in Table 6.  In all examples studied, both acute POAF in canines and 
chronic AF in canines and humans, the phosphorylation-dependent loss of TASK-1 current was 
associated with atrial fibrillation.  This research has therefore implicated TASK-1 as a possible 
contributor to AF initiation and maintenance, and merits further in vivo studies as to the 
therapeutic potential of TASK-1 activation as an antiarrhythmic strategy. 
 
T383 is an hTASK-1 Phosphorylation Site 
In vitro phosphorylation experiments identified T383 in the hTASK-1 distal C-terminus 





PKCε phosphorylation of the TASK-1 distal C-terminus-GST fusion protein, although 
phosphorylation at this site also inhibits the channel.  No other direct phosphorylation 
modifications were detected by LC-MS/MS analysis of the PKCε-phosphorylated fusion protein.  
These experiments were performed in an artificial system, and technical difficulties prevented 
the analysis of the full C-terminus, full-length hTASK-1 channel, or native TASK-1 channel for 
phosphorylation site identification.  Therefore, the possibility could not be discounted that the in 
vitro assay system did not reflect physiological signaling.  However, separate studies 
demonstrated that the T383 site was not phosphorylated by recombinant PKCα, PKA, or RSK2 
in similar in vitro kinase assays of the 15-distal residues of hTASK-1 fused to GST (Mant et al, 
2011), indicating that this phosphorylation is specific to the epsilon isoform, and is likely not a 
result of an overly promiscuous experimental system.   
Furthermore, development of the pT383 PSSA allowed the immunodetection of 
phosphorylated T383 in heterologous systems and native tissue.  Phosphorylation of 
heterologusly expressed hTASK-1 at T383 was demonstrated in cultured cells treated with C-
PAF, and PKC-dependent phosphorylation of the native canine TASK-1 channel at T383 was 
demonstrated in atrial tissue treated with C-PAF in vitro.  Moreover, increased T383 
phosphorylation was detected after experiments to induce POAF in an in vivo canine model.  
Therefore, T383 is a phosphorylation site targeted directly by PKCε and downstream of C-PAF 
signaling, and phosphorylation at this site is regulated in the intact animal. 
Other studies have previously investigated the role of PKC signaling in TASK-1 
inhibition.  While studies in some heterologous expression systems have found no PMA-





dependent inhibition of TASK-1, or direct inhibition by other Gq signaling components 
(reviewed by Mathie, 2007).  Native TASK-1 has been shown to be inhibited downstream of 
activation of the G protein-coupled endothelin-1 receptor  in human pulmonary artery smooth 
muscle cells, which requires PKC and its upstream mediators PLC, PIP2, and DAG (Tang et al, 
2009).  This TASK-1 inhibition corresponded with cell depolarization and an increase in 
phospho-threonine signal in immunoblots of immunoprecipitated channel.  Other studies found 
that TASK-1 expressed in xenopus oocytes is inhibited downstream of G-coupled 
lysophosphatidic acid and angiotensin II receptors.  Although the inhibition was PLC-dependent, 
it was independent of DAG or IP3, indicating a role for direct inhibition through PLC (Czirják G 
et al, 2001).  Further studies indicated that PIP2 hydrolysis subsequent to PLC activation may be 
directly responsible for inhibition of TASK-1 (Lopes et al, 2005).  Although the direct action of 
upstream signaling components was not investigated in this thesis, the fact that PKCε inhibition 
blocks the C-PAF-sensitivity of TASK-1 current (Fig 8), and that treatment with C-PAF results 
in an increase in pT383 signal in western blots of CHO cells and a PKC-dependent increase in 
pT383 signal in western blots of atrial tissue (Fig 11), indicates that C-PAF dependent inhibition 
of TASK-1 is largely mediated through a phosphorylation event. 
 
TASK-1 inhibition in the initiation of atrial fibrillation: the canine POAF model 
A canine POAF model was implemented in which an open-chest atriotomy was 
performed, and AF was induced in a majority of dogs three days later by brief bursts of rapid 





and this study has implicated phosphorylation-dependent TASK-1 inhibition with the initiation 
of POAF.   
Neutrophil infiltration into atrial myocardium was significantly increased, rising by 38-
fold, after the induction of POAF, as measured by the enzymatic activity of neutrophil 
myeloperoxidase enzyme (Fig 13).  This correlates well to findings in human patients, where 
peri-operative levels of circulating neutrophils  were found to be higher in patients undergoing 
coronary artery bypass grafting (CABG) surgery that went on to develop AF, compared to those 
who remained in NSR (Fontes et al, 2005).  Although complete mapping of the fibrillating atria 
were not performed in this thesis or by Ishii et al, in a similar model in which a y-shaped incision 
was made across the intercaval region and across the right atrium, burst pacing or premature 
stimuli resulted in a stable reentrant circuit in the right atrial ring above the tricuspid valve 
(Frame et al, 1986).  In the current POAF model, mapping studies have demonstrated that the 
peri-operative procedure causes a significant increase in heterogeneity of conduction before the 
induction of AF (Ishii et al, 2005).  Treatment with corticosteroids, and the resulting decrease in 
the level of neutrophil infiltration into the atrial myocardium, decreased the heterogeneity to 
levels that were similar to unoperated control animals.  Similarly, a meta-analysis of clinical data 
concluded that treatment of human patients undergoing CABG and/or valve repair procedures 
treated with moderate to high doses of corticosteroids showed a decreased incidence of POAF 
(Marik and Fromm, 2009).  Mapping studies in human patients during cardiac surgery, who go 
on to either remain in NSR or to develop POAF, found that there is an association between 
conduction delay and nonuniform activation before the onset of the disease, and subsequent 
development of POAF (Sakamoto et al, 2006).  This suggests that the substrate for the 





related inflammation and tissue damage, and our canine model is therefore unable to completely 
recapitulate the human disease.  Indeed, in human patients, the arrhythmia develops 
spontaneously, whereas in the canine model, performed in otherwise healthy and relatively 
young animals with no underlying cardiovascular pathology, AF requires brief burst pacing in 
order to manifest.   
In the current study, induction of POAF was associated with a complete loss of TASK-1 
current from isolated right atrial myocytes (Fig 15A, right panel, filled circles).  Since it is 
known that activation of the PAF receptor results in TASK-1 inhibition, it is possible that 
signaling resulting from neutrophil-derived PAF is responsible, at least in part, for the loss of 
TASK-1 current.  Addition of phosphatase to the patch pipette resulted in a restoration of 
currents to levels similar to those seen in pre-operative control cells (Fig 15A, right panel, open 
circles), suggesting that phosphorylation of T383, identified as a phosphorylation target 
downstream of C-PAF, might be responsible for the phosphorylation-dependent loss of TASK-1 
current.  Indeed, immunoblotting of right atrial tissue revealed a large increase in pT383 levels 
relative to total TASK-1 (Fig 17).  Total TASK-1 protein signal decreased on average (Fig 16B, 
top panel), but since current was restored to normal levels upon phosphatase treatment, there was 
likely minimal change in the absolute number of available channels at the membrane, and 
instead the decreased signal either reflects merely a relative decrease in TASK-1 levels, as the 
protein loaded onto the gel from post-operative samples was disproportionately composed of 
increased pro-inflammatory and pro-fibrotic proteins, or a decrease in a separate pool of TASK-1 
protein sequestered away from the membrane.  Since increased phosphorylation of T383 
corresponded to the phosphorylation-dependent loss of TASK-1 current, it appeared that 





However, the data from animals in which surgical and pacing protocols failed to induce AF 
complicates that story. 
 
POAF model: successful versus unsuccessful AF induction 
In a small number of animals, the surgical and pacing protocols failed to induce POAF.  
In atrial myocytes from these animals, TASK-1 was not inhibited (Fig 19, right panel), but 
pT383 signal increased (Fig 21).   
Patch-clamp data and tissue for immunoblotting analysis was available for only 4 of these 
failed-induction dogs.  The average level of TASK-1 current in cells from these dogs was no 
different from those of pre-operative control tissue, but there was significant cell-to-cell 
variation.  TASK-1 current density was either extremely high (n=1; 2.57 pA/pF at +30 mV), 
similar to control (n=7; 0.22-0.57 pA/pF at +30mV), lower than control (n=2; 0.12-0.14 pA/pF), 
or similar to AF (n=2; <0.1pA/pF).  It is possible that pT383 is still a target for phosphorylation-
dependent inhibition, albeit heterogeneous, in atrial tissue from these animals, and the resulting 
pT383 signal is indistinguishable from the stronger more homogenous T383 phosphorylation in 
tissue from dogs with POAF, due to the merely semi-quantitative nature of immunoblotting and 
the small number of animals with failed induction available for analysis. The level of pT383 may 
be sufficient, on the global scale, to result in western blot band intensity that is indistinguishable 
from successful AF induction, but not large enough, on the cell-by-cell level, to resemble cells 
from dogs with successful POAF induction in their TASK-1 current density.  However, it is also 
possible that the level of T383 phosphorylation truly is the same whether induction of POAF is 





Given the intriguing results that pT383 band intensity is increased to a similar extent 
whether POAF induction is successful or not, it is possible that phosphorylation of TASK-1 at 
T383 is not associated with the development of atrial arrhythmias, and that there is an alternate 
phosphorylation site responsible for the phosphorylation-dependent loss of TASK-1 current seen 
in cells after POAF induction but not in cells after POAF failed to be induced.  There is a 
precedent in K2P channel regulation for sequential phosphorylation at two different 
phosphorylation sites.   Murbartián et al (2005) found that in HEK293 cells, the previously 
identified PKA site serine-330 (S330) in the K2P channel mTREK-1 was only sufficient for 
receptor-mediated channel inhibition when an additional serine at 300 (S300) was allowed to be 
phosphorylated.  The model inferred from their data suggested that S330 is initially targeted, 
resulting in a conformational change that allows subsequent phosphorylation at S300, which 
ultimately determines the conductance state of the channel.  It seems plausible, then, that 
phosphorylation of TASK-1 at T383 is a similar priming step, allowing the sequential 
phosphorylation of an alternate site which correlates more directly with channel activity.  By this 
reasoning, the increase in pT383 signal seen in tissue from dogs with failed POAF induction is a 
necessary first step toward loss of TASK-1 current, but unknown factors (possibly related to the 
decreased level of neutrophil infiltration into the myocardium) which would have resulted in the 
final inhibitory phosphorylation, were missing. A schematic of this model of sequential 
phosphorylation is shown in Fig 29, where cells from dogs with failed POAF induction would be 
represented by the top panel, with PKC-dependent phosphorylation of T383, but no subsequent 
phosphorylation of the second site to inhibit TASK-1.  To test this conjecture, experiments 
would need to be done expressing TASK-1 with a phospho-mimetic mutation at T383, alone and 





phosphorylation sites.  This would determine whether the T383-phosphorylated channel is 
nonconducting, when modulated alone or in combination with other sites.  These experiments 
would require careful controls to confirm that any decrease in TASK-1 current density is due to 
the phospho-mimic, and not a failure to fold or localize to the membrane properly. 
An alternate explanation for the discrepancy between pT383 signal and TASK-1 current 
levels is that TASK-1 is phosphorylated at T383, and this phosphorylation event promotes 
internalization of the channel for proteolysis, or some other sequestering of the channel away 
from the plasma membrane, and we are observing different time-points of this internalization 
process in successful and failed induction dogs.  According to this hypothesis, at the peak of the 
inflammatory response, when neutrophil accumulation, and therefore presumably PAF signaling 
levels, are at their highest, AF is easier to induce.  The T383 phosphorylated channels are still in 
the plasma membrane and contribute to the phosphorylation-dependent loss of TASK-1 current.  
At a time after the peak of the inflammatory response, neutrophil accumulation, and therefore 
presumably PAF signaling levels, are lower and AF is more difficult to induce.  Subsequent to 
activation, PAF receptors may be phosphorylated and internalized, further contributing to a 
decrease in PAF signaling (Stafforini et al, 2003).  At this time, T383-phosphorylated channels 
have begun to be internalized, and replaced at the membrane by a pool of nonphosphorylated 
TASK-1, with the result that TASK-1 currents do not display on average the phosphorylation-
dependent inhibition seen in AF, but T383 phosphorylation in the crude membrane preparation is 
still detectable by western blot.  A schematic of this hypothesized model is depicted in Fig 30, 
with the top panel representing the possible distribution of phosphorylated and 
nonphosphorylated TASK-1 channels at the time of peak inflammation, when we would expect 





POAF induction would be less successful.  An alternative hypothesis explaining the difference in 
T383 phosphorylation in failed versus successful induction of POAF posits that instead of seeing 
different time-points in the internalization of T383-phosphorylated TASK-1 channels, we are 
observing a general dysfunction in recycling machinery associated with AF.  In situations of 
lower levels of inflammation, as seen after failed peri-operative AF induction, T838-
phosphorylated TASK-1 channels are internalized for recycling, and replaced at the membrane 
with functional nonphosphorylated channels.  This results in the lack of phosphorylation-
dependent channel inhibition at the plasma membrane in patch-clamp studies, but the detection 
of T383-phosphorylated channels in immunoblots of crude membrane preparations.  When 
POAF is successfully induced, this protein recycling machinery is defective, possibly related to 
larger amounts of inflammation and tissue injury.  This results in a buildup of T383-
phosphorylated channels in the plasma membrane, consistent with the observed phosphorylation-
dependent inhibition of TASK-1 in patch-clamp studies.  A schematic of this hypothesized 
model is depicted in Fig 31.  These explanations are of course speculative, and the intracellular 
distribution of the TASK-1 protein detected in immunoblotting experiments is not known. 
Although a crude-membrane fractionation was performed, and we can therefore assume that the 
TASK-1 we are detecting is not nuclear or located in small vesicles, it is not certain what 
proportion of the channel that we detect by western blotting are localizing to the plasma 
membrane, as opposed to other membrane organelles, such as endocytic protein recycling 
compartments.  Experiments studying the signaling components required for reverse transport of 
the channels and the time-course of the inflammatory response, AF propensity, T383 





subcellular localization of phosphorylated and nonphosphorylated TASK-1 channels by 
immunofluorescence. 
 
The maintenance of atrial fibrillation: the canine rapid pacing AF model and human 
patients 
This work has revealed an association between the phosphorylation-dependent loss of 
TASK-1 current and chronic AF.  TASK-1 current was present in right atrial cells from 
unoperated control dogs and from sham-paced dogs in NSR, but was absent in cells from dogs 
with sustained AF following rapid atrial pacing (Fig 24, filled circles).  Similarly, TASK-1 
current was present in cells from the left atria of human valve disease patients in NSR, but was 
absent in cells from patients with a history of AF (Fig 27, filled circles).  In both human patients 
and the canine model, TASK-1 current was restored upon treatment with phosphatase (Fig 24 
and 27, open circles).  This phosphorylation-dependent loss of TASK-1 current occurred without 
a corresponding increase in neutrophil accumulation in atrial tissue (Fig 23 and 26), or in pT383 
signal in tissue homogenates (Fig 25 and 28). 
Other investigators have found an increase in myeloperoxidase levels in the right atrial 
appendage of patients with AF undergoing coronary artery bypass grafting surgery as compared 
to their counterparts in NSR (Rudolph et al, 2010).  It's unclear whether the discrepancy in 
results is due to the location of the tissue specimens (right atrial appendage versus left atrial free 
wall), the primary underlying pathology (coronary artery disease versus mitral valve disease), or 
the detection technique (immunohistochemistry versus enzymatic assay requiring functional 





Although the role of inflammation in the maintenance of AF is not as well established as its role 
in the initiation of the disease, various studies have found associations between chronic AF and 
C-reactive protein (Sata et al, 2004; Chung et al, 2001). 
Phosphorylation at T383 does not appear to be responsible for the phosphorylation-
dependent loss of TASK-1 current seen in atrial myocytes from human patients or canines with 
chronic AF.  It is not clear what phosphorylation event is resulting in channel inhibition, but a 
study of patients with AF have shown an increase in protein levels of PKCε, and no increase in 
α, β1 or δ PKC isoforms (Voigt et al, 2007).  Therefore, it is possible that a PKCε 
phosphorylation site elsewhere on the channel, proximal to the 45-residue portion of hTASK-1 
that was tested in in vitro kinase assays, contributes to TASK-1 inhibition.  It is also possible that 
a phosphorylation event on a separate protein causes a change in the way it interacts with TASK-
1, thus inhibiting TASK-1 current flow.  Other kinases have also been shown to be upregulated 
in atrial fibrillation, including calmodulin kinase II (reviewed by Dobrev and Wehrens, 2010), 
the tyrosine kinase Src (Rao et al, 2009), and mitogen-activated protein kinase (reviewed by 
Novo et al, 2008). 
 
Relationship between AF induction, loss of TASK-1 current, and pT383 phosphorylation: 
POAF versus chronic AF 
In cells from the canine rapid-pacing model of sustained AF, as well as in cells from 
human patients with chronic AF, TASK-1 was inhibited in a phosphorylation-dependent manner, 
but there was no increase in myocardial neutrophil infiltration or T383 phosphorylation relative 





responsible for loss of TASK-1 current in isolated atrial myocytes is likely not phosphorylation 
at T383.  It was shown in this study that while T383 was necessary for C-PAF-dependent 
inhibition of hTASK-1, it was not responsible for inhibition of TASK-1 downstream of the 
isoform-nonspecific PKC activator, PMA.  Therefore, it appears likely that there are other 
phosphorylation sites in TASK-1 that play a role in channel inhibition.  In experiments in which 
TASK-1 was immunoprecipitated from canine atrial tissue homogenates, the TASK-1 band 
demonstrated immunoreactivity for both phospho-threonine and phospho-serine (Fig 1).  S358, 
which was shown to be necessary for PMA-dependent TASK-1 inhibition (Fig 7B), is a likely 
candidate.   
It is also possible that S358, or another phosphorylation site that has not yet been 
investigated, is involved in a sequential phosphorylation step like that described above, and 
illustrated in Fig 29.  Phosphorylation of T383 by PKCε primes the channel, allowing a 
conformational change that increases availability of the second phosphorylation site.  At the time 
point in chronic AF in which samples are taken from the canine rapid-pacing model or from 
diseased human tissue, phosphorylation at the priming site, T383, is no longer being regulated, 
whereas phosphorylation at the subsequent site is responsible for the loss of TASK-1 current.  In 
addition, there are a number of consensus phosphorylation sites for other kinases in the hTASK-
1 C-terminus, so it is likely that other signaling cascades are acting on the channel in the highly 
dysfunctional milieu of AF.   
Therefore, it is reasonable to interpret that phosphorylation at T383 is involved in the 






K+ channel inhibition and AF 
The most commonly discussed hypothesized role of potassium currents in arrhythmias is 
that activation of outward potassium currents shortens the action potential and refractory period, 
allowing reentry (reviewed by Ravens and Cerbai, 2008).  Accordingly, Class III antiarrhythmics 
such as amiodarone and sotalol act at least in part by inhibiting potassium currents to prolong the 
action potential duration and increase the refractory period (reviewed by Gillis et al, 2011).  
According to this theory, the TASK-1 inhibition associated with peri-operative AF could be a 
protective compensatory mechanism.  Indeed, it is not known at this time whether inhibition of 
TASK-1 is a contributor to the initiation or maintenance of AF, or a result of AF.  However, 
other groups have found a link between loss of potassium currents and atrial arrhythmias.  A 
mutation disrupting membrane trafficking in minK, an accessory protein of KvLQT1 allowing 
formation of functional IKs, is linked to clinical AF (Erlich et al, 2005), and mice deficient in the 
small conductance calcium-activated potassium channel SK2 have been shown to be susceptible 
to AF and EADs (Li et al, 2009).  There is emerging evidence to support a role for potassium 
channel inhibition in the promotion of AF (reviewed by Nattel, 2009).  Decreased K+ currents 
can promote the initiation or maintenance of arrhythmias by prolonging the action potential 
duration (APD) and causing early after-depolarizations (EADs), spurring ectopic beats and 
inhomogeniety of refractoriness that can lead to reentry.  Prolonged ventricular APDs were 
observed in the TASK-1 knockout mouse (Donner et al, 2001; Decher et al, 2011), and 
prolonged APDs and EADs were also seen in our lab in isolated wild-type mouse ventricular 
myocytes treated with the TASK-1 inhibitor methanandamide (Barbuti et al, 2002).  Putzke et al 
(2007) also observed prolonged APDs after inhibition of TASK-1 in rat ventricular myocytes.  





isolated rat ventricular myocytes, confirming the potential for a small conductance leak channel 
to have a large impact on repolarization.  However, the properties of the ventricular action 
potential differ greatly from the atrial action potential.  Relative to ventricular myocytes, atrial 
myocytes have a higher density of IKur and IKAch, and a lower density of IK1 (reviewed by Nattel, 
2009).  Atrial cells display a shorter plateau phase of the action potential, at a more negative 
voltage, and a steeper slope of repolarization.  During the  plateau phase of a ventricular action 
potential, there is little change in membrane voltage and little net current flow, resulting in a 
vulnerable period during which small changes in ion channel activity (such as inhibition of 
TASK-1) can have a large effect on membrane voltage and promote EADs.  Atrial myocytes lack 
this prolonged plateau phase vulnerability.     
 
The role of TASK-1 in differentially polarized cells 
The open rectifier properties of TASK-1, i.e. that the current flow through the channel 
follows the Nernst prediction for K+ leak, mean that in a cell with a resting membrane potential 
near the reversal potential for K+, near -80 mV, there will be little net flow through TASK-1.  
Therefore TASK-1 would be expected to contribute very little to the resting membrane potential 
in well polarized cells, and TASK-1 inhibition would not be expected to substantially alter the 
excitability of such cells.  However, human atrium demonstrates a range of resting membrane 
potentials, from -80 mV to -50 mV (Mary-Rabine et al, 1983).  In relatively poorly polarized 
cells, TASK-1 may play a substantially larger role in maintaining the membrane potential, and its 
inhibition could therefore cause a larger depolarization.  Furthermore, at relatively depolarized 





al, 1994), increasing the relative contribution of TASK-1.  Indeed, unpublished pilot data (Dr. 
Sosunov and Dr. Anyukhovsky, Rosen lab) have suggested that inhibition of TASK-1 with 
methanandamide has no effect on intact canine atrial tissue with a relatively negative resting 
membrane potential of -84 mV, but causes measurable depolarization (approximately 5 mV) of 
atrial tissue with a less negative potential of -73 mV.  
One potential repercussion for this effect could relate to the behavior of the sodium 
channel.  It has been shown in canine atrium that for every 5 mV depolarization in resting 
membrane potential (within the range from -80 to -65 mV), there is a reduction of sodium 
channel availability by roughly half.  Thus, poorly polarized cells may be expected to have 
reduced sodium current.  Furthermore, in some models of AF, an additional reduction in INa 
current density has been observed, independent of the voltage-dependent channel inactivation 
(Gaspo et al, 1997; Yagi et al, 2002).  The combined effects of the heterogeneity of resting 
membrane voltage and the loss of endogenous sodium channels yields an atrial substrate with 
highly variable sodium channel availability at rest, which would result in slowed and 
heterogeneous conduction.  Further depolarization by TASK-1 inhibition would result in even 
fewer sodium channels being available for activation in less well polarized regions, resulting in 
even slower activation and greater heterogeneity of conduction velocity, consistent with the 
conduction heterogeneity observed in canine peri-operative AF (Ishii et al, 2005).  Collaborators 
have adjusted existing computer simulations of ion currents contributing to the canine atrial 
action potential (Courtemanche et al, 1998) to include TASK-1 and to allow for a range of 
resting membrane potentials (unpublished data; Dr. Chris Clausen and Dr. Ira Cohen, SUNY 
Stony Brook).  The unpublished pilot data (Sosunov, Anyukhovsky, and Rosen) has confirmed 





action potential upstroke velocity (Vmax) of atrium with relatively negative resting potentials, 
TASK-1 inhibition causes a noticeable decrease in Vmax in less polarized tissue.  Slower 
conduction velocity favors reentry, by allowing refractory periods of surrounding tissue to end 
before a propagating wave has moved on. 
Less well polarized tissue has been identified in atrium from human patients, as discussed 
above.  While the resting membrane potentials of atrial myocytes isolated from human patients 
or from canines with acute or chronic AF were not comprehensively studied in this thesis, it is 
possible that heterogeneity exists.  In human patients, less negative resting potential was 
associated with increased atrial dilation and pressure, increased p-wave duration, and increased 
incidence of arrhythmias (Mary-Rabine et al, 1983).  It is likely, therefore, that the range of 
resting membrane potentials of the patients in our study, who exhibited increased left atrial 
diameter and atrial fibrillation, resembled the cohort studied by Mary-Rabine et al.  While the 
canine rapid-pacing model of chronic AF has not been reported to result in decreased resting 
membrane polarization, these studies generally analyze tissue from a single location in the 
atrium, and may not reveal heterogeneity.  Indeed, heterogeneity in resting membrane potentials 
is known to exist in the normal canine atrium, depending on the anatomical location of the cells 
(reviewed by Bodyen, 2001).  The pulmonary vein cardiomyocytes are thought to be an 
especially important source of arrhythmogenic triggered activity, and have less polarized resting 
membrane potentials (Ehrlich et al, 2003).  It is also possible that in the canine peri-operative AF 
model, proinflammatory signaling causes changes in resting membrane potential, contributing to 
the inflammation-dependent heterogeneity of conduction observed by Ishii, et al.  Therefore, in 





well polarized.  In these areas, TASK-1 inhibition would be expected to cause a further 
depolarization, thus decreasing conduction velocity and contributing to reentry. 
 
Implications for the prevention and treatment of AF 
Loss of TASK-1 current from isolated myocytes was associated with AF in every model 
studied, both in canine models of the acute (POAF) and chronic (rapid atrial pacing) disease, and 
in human patients.  In the instances when AF was not successfully induced by our procedures, 
TASK-1 current in atrial myocytes was on average similar to levels observed in cells from 
normal pre-operative control tissue (Fig 19A, right panel).  Therefore, the loss of TASK-1 
current may contribute to the etiology of the disease, as discussed above.  Since both acute and 
chronic models of the disease display a loss of TASK-1 current, the channel could be a target in 
both the prevention of AF onset post-operatively, and in treatment of the chronic disease.  
Furthermore, in our model of AF with a clear acute inflammatory component, POAF, a putative 
signaling cascade has been implicated.  Previous research identified TASK-1 as the 
proinflammatory PAF-sensitive target in isolated ventricular myocytes (Barbuti et al, 2002), and 
PAF-dependent channel inhibition required the epsilon isoform of PKC (Besana et al, 2004).  
This thesis has further identified T383 as a direct PKCε phosphorylation target, and detected a 
PKC-dependent increase in phosphorylation at this site after C-PAF treatment of atrial tissue.  
Therefore, the work in this thesis, when combined with previous research from this lab, has 
provided strong support for the investigation of PAFR antagonism or TASK-1 channel activation 





Previous work in animal models found that PAFR antagonists are effective at preventing 
ventricular arrhythmias after ischemia and reperfusion (Koltai et al, 1991; Qayumi et al, 1998; 
Haines et al, 2000).  However, these studies have largely been abandoned due to unfavorable 
effects on coronary blood flow and QT duration.  Despite more recent work with the PAFR 
antagonist Nupafant, demonstrating that coronary vasodilation and prolonged QT interval are not 
necessarily class effects (Baker et al, 2006), little work has been done recently to further PAFR 
antagonism as an antiarrhythmic therapeutic strategy in peri-operative AF.  This current work, 
identifying TASK-1 as a physiologically relevant downstream target of inflammation and PAFR 
signaling, could provide a more direct way to prevent peri-operative AF with fewer unwanted 
effects.  Therapies aimed at preventing TASK-1 inhibition or restoring this small conductance 






Figure 29.  Sequential phosphorylation: a proposed model for the role of phosphorylation 
at T383 in AF. 
In atrial tissue from dogs in which surgery and pacing failed to induce POAF, phosphorylation of 
TASK-1 at T383 was demonstrated to be increased, but there was no increase in 
phosphorylation-dependent TASK-1 inhibition.  One possible explanation is that 
phosphorylation at T383 is necessary, but not sufficient for TASK-1 inhibition.  Phosphorylation 
at T383 is a "priming" step (A) that allows a conformational change that allows access to a 
second phosphorylation site.  When an unknown other factor stimulates a second 
phosphorylation (B), TASK-1 is inhibited in a phosphorylation-dependent manner, and TASK-1 
inhibition then contributes to vulnerability to POAF induction.  Tissue from dogs with failed 
POAF induction would be expected to resemble panel A, whereas tissue from dogs with 


































Figure 30.  Internalization: a proposed model for the role of phosphorylation at T383 in AF 
over time. 
In atrial tissue from dogs in which surgery and pacing failed to induce POAF, phosphorylation of 
TASK-1 at T383 was demonstrated to be increased, but there was no increase in 
phosphorylation-dependent TASK-1 inhibition.  One possible explanation is that the TASK-1 
channels phosphorylated at T383 have been internalized, so the phosphorylation state of 
channels analyzed in western blot analysis do not reflect the phosphorylation state of channels in 
the membrane.  A time-dependent internalization of phosphorylated channels could explain this.  
A.  At peak levels of peri-operative inflammation, PAF signaling results in phosphorylation of 
T383.  TASK-1 at the membrane is inhibited, and contributes to the vulnerability of tissue to 
POAF induction, and burst pacing successfully induces AF.  B.  After levels of inflammation 
have begun to decrease, there is less PAF signaling promoting T383 phosphorylation of TASK-1 
in the membrane.  Previously phosphorylated channels have begun to be internalized, but not yet 
degraded, and replaced at the membrane with new nonphosphorylated TASK-1.  TASK-1 at the 
membrane is not inhibited, and therefore does not contribute to vulnerability to POAF induction, 































Figure 31.  Dysfunctional internalization: a proposed model for the role of phosphorylation 
at T383 in AF. 
 In atrial tissue from dogs in which surgery and pacing failed to induce POAF, phosphorylation 
of TASK-1 at T383 was demonstrated to be increased in crude membrane preparations, but there 
was no increase in phosphorylation-dependent TASK-1 inhibition.  One possible explanation is 
that the TASK-1 channels phosphorylated at T383 are being internalized, so the phosphorylation 
state of channels analyzed in western blot analysis do not reflect the phosphorylation state of 
channels in the plasma membrane.  A defect in the protein recycling machinery associated with 
AF could explain this.  A.  Inflammation is associated with increased phosphorylation of TASK-
1 at T383.  These phosphorylated channels are internalized and replaced at the plasma membrane 
by nonphosphorylated functional channels.  While T383 phosphorylation is detected in 
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